Finely powdered native hydrous magnesium silicate. It is used as a dusting powder, either alone or with starch or boric acid, for medicinal and toilet preparations. It is also an excipient and filler for pills, tablets, and for dusting tablet molds. (From Merck Index, 11th ed)
Messages between computer users via COMPUTER COMMUNICATION NETWORKS. This feature duplicates most of the features of paper mail, such as forwarding, multiple copies, and attachments of images and other file types, but with a speed advantage. The term also refers to an individual message sent in this way.
Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.
An organoplatinum compound that possesses antineoplastic activity.
The production of adhesions between the parietal and visceral pleura. The procedure is used in the treatment of bronchopleural fistulas, malignant pleural effusions, and pneumothorax and often involves instillation of chemicals or other agents into the pleural space causing, in effect, a pleuritis that seals the air leak. (From Fishman, Pulmonary Diseases, 2d ed, p2233 & Dorland, 27th ed)
Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.
Systems where the input data enter the computer directly from the point of origin (usually a terminal or workstation) and/or in which output data are transmitted directly to that terminal point of origin. (Sippl, Computer Dictionary, 4th ed)
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Tumors or cancer of the ANAL CANAL.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Tumors or cancer of the LUNG.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
The homogeneous mixtures formed by the mixing of a solid, liquid, or gaseous substance (solute) with a liquid (the solvent), from which the dissolved substances can be recovered by physical processes. (From Grant & Hackh's Chemical Dictionary, 5th ed)
Prudent standard preventive measures to be taken by professional and other health personnel in contact with persons afflicted with a communicable disease, to avoid contracting the disease by contagion or infection. Precautions are especially applicable in the diagnosis and care of AIDS patients.
Use of written, printed, or graphic materials upon or accompanying a product or its container or wrapper. It includes purpose, effect, description, directions, hazards, warnings, and other relevant information.
Introduction of substances into the body using a needle and syringe.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Organic compounds which contain platinum as an integral part of the molecule.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Dimers found in DNA chains damaged by ULTRAVIOLET RAYS. They consist of two adjacent PYRIMIDINE NUCLEOTIDES, usually THYMINE nucleotides, in which the pyrimidine residues are covalently joined by a cyclobutane ring. These dimers block DNA REPLICATION.
Lists of persons or organizations, systematically arranged, usually in alphabetic or classed order, giving address, affiliations, etc., for individuals, and giving address, officers, functions, and similar data for organizations. (ALA Glossary of Library and Information Science, 1983)
Exploitation through misrepresentation of the facts or concealment of the purposes of the exploiter.
Concept referring to the standardized fees for services rendered by health care providers, e.g., laboratories and physicians, and reimbursement for those services under Medicare Part B. It includes acceptance by the physician.
Payment by a third-party payer in a sum equal to the amount expended by a health care provider or facility for health services rendered to an insured or program beneficiary. (From Facts on File Dictionary of Health Care Management, 1988)
Tumors or cancer of the UVEA.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Nucleotides in which the base moiety is substituted with one or more sulfur atoms.
Tumors or cancer of the LIVER.
Glioma derived from EPENDYMOGLIAL CELLS that tend to present as malignant intracranial tumors in children and as benign intraspinal neoplasms in adults. It may arise from any level of the ventricular system or central canal of the spinal cord. Intracranial ependymomas most frequently originate in the FOURTH VENTRICLE and histologically are densely cellular tumors which may contain ependymal tubules and perivascular pseudorosettes. Spinal ependymomas are usually benign papillary or myxopapillary tumors. (From DeVita et al., Principles and Practice of Oncology, 5th ed, p2018; Escourolle et al., Manual of Basic Neuropathology, 2nd ed, pp28-9)
A performance measure for rating the ability of a person to perform usual activities, evaluating a patient's progress after a therapeutic procedure, and determining a patient's suitability for therapy. It is used most commonly in the prognosis of cancer therapy, usually after chemotherapy and customarily administered before and after therapy. It was named for Dr. David A. Karnofsky, an American specialist in cancer chemotherapy.
Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
A spasm of the diaphragm that causes a sudden inhalation followed by rapid closure of the glottis which produces a sound.
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
The thin, horny plates that cover the dorsal surfaces of the distal phalanges of the fingers and toes of primates.
A filament-like structure consisting of a shaft which projects to the surface of the SKIN from a root which is softer than the shaft and lodges in the cavity of a HAIR FOLLICLE. It is found on most surfaces of the body.
Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.
A tube-like invagination of the EPIDERMIS from which the hair shaft develops and into which SEBACEOUS GLANDS open. The hair follicle is lined by a cellular inner and outer root sheath of epidermal origin and is invested with a fibrous sheath derived from the dermis. (Stedman, 26th ed) Follicles of very long hairs extend into the subcutaneous layer of tissue under the SKIN.

Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. (1/1928)

Testicular germ cell tumours are hypersentive to chemotherapy and cell lines derived from these tumours are chemosensitive in vitro. We have previously shown that these cell lines express undetectable levels of the suppressor of apoptosis Bcl-2 and relatively high levels of the apoptosis inducer Bax (Chresta et al., 1996). To determine whether the absence of Bcl-2 in these cell lines makes them highly susceptible to drug-induced apoptosis, Bcl-2 was expressed ectopically in the 833K testicular germ cell tumour cell line. Stable overexpressing clones were isolated and three clones were studied further. Surprisingly, Bcl-2 overexpressing cells were sensitized to chemotherapy-induced apoptosis compared to the parental and vector control cells. Analysis of potential mechanisms of sensitization revealed there was a reciprocal downregulation of the endogenously expressed Bcl-X(L) in the Bcl-2 overexpressing clones. Downregulation of Bcl-X(L) to the same extent using antisense oligonucleotides enhanced etoposide-induced apoptosis by twofold. Our results indicate that Bcl-2 and Bcl-X(L) have different abilities to protect against chemotherapy-induced apoptosis in testicular germ cell tumours. In contrast to findings in some tumour cell types, Bcl-2 did not act as a gatekeeper to prevent entry of p53 to the nucleus.  (+info)

A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. (2/1928)

Multinuclear platinum compounds have been designed to circumvent the cellular resistance to conventional platinum-based drugs. In an attempt to examine the cellular basis of the preclinical antitumor efficacy of a novel multinuclear platinum compound (BBR 3464) in the treatment of cisplatin-resistant tumors, we have performed a comparative study of cisplatin and BBR 3464 in a human osteosarcoma cell line (U2-OS) and in an in vitro selected cisplatin-resistant subline (U2-OS/Pt). A marked increase of cytotoxic potency of BBR 3464 in comparison with cisplatin in U2-OS cells and a complete lack of cross-resistance in U2-OS/Pt cells were found. A detailed analysis of the cisplatin-resistant phenotype indicated that it was associated with reduced cisplatin accumulation, reduced interstrand cross-link (ICL) formation and DNA platination, microsatellite instability, and reduced expression of the DNA mismatch repair protein PMS2. Despite BBR 3464 charge and molecular size, in U2-OS and U2-OS/Pt cells, BBR 3464 accumulation and DNA-bound platinum were much higher than those observed for cisplatin. In contrast, the frequency of ICLs after exposure to BBR 3464 was very low. The time course of ICL formation after drug removal revealed a low persistence of these types of DNA lesions induced by BBR 3464, in contrast to an increase of DNA lesions induced by cisplatin, suggesting that components of the DNA repair pathway handle the two types of DNA lesions differently. The cellular response of HCT116 mismatch repair-deficient cells was consistent with a lack of influence of mismatch repair status on BBR 3464 cytotoxicity. Because BBR 3464 produces high levels of lesions different from ICLs, likely including intra-strand cross-links and monoadducts, the ability of the triplatinum complex to overcome cisplatin resistance appears to be related to a different mechanism of DNA interaction (formation of different types of drug-induced DNA lesions) as compared with conventional mononuclear complexes rather than the ability to overcome specific cellular alterations.  (+info)

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. (3/1928)

PURPOSE: Platinum-based chemotherapy currently represents standard treatment for advanced non-small-cell lung cancer. Gemcitabine is one of the most interesting agents currently in use in advanced non-small-cell lung cancer, and high response rates have been reported when it is administered in combination with cisplatin. The aim of the present study was to evaluate the combination of gemcitabine and carboplatin in a phase I-II study. PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB-IV non-small-cell lung cancer received carboplatin at area under the concentration-time curve (AUC) 5 mg/mL/min and gemcitabine at an initial dose of 800 mg/m2, subsequently escalated by 100 mg/m2 per step. Gemcitabine was administered on days 1 and 8 and carboplatin on day 8 of the 28-day cycle. Dose escalation proceeded up to dose-limiting toxicity (DLT), which was defined as grade 4 neutropenia or thrombocytopenia or grade 3 nonhematologic toxicity. RESULTS: Neutropenia was DLT, inasmuch as it occurred in three of five patients receiving gemcitabine 1,200 mg/m2. Nonhematologic toxicities were mild. Gemcitabine 1,100 mg/m2 plus carboplatin AUC 5 was recommended for phase II studies. An objective response was observed in 13 (50%) of 26 patients, including four complete responses (15%) and nine partial responses (35%). Median duration of response was 13 months (range, 3 to 23 months). Median overall survival was 16 months (range, 3 to 26 months). CONCLUSION: The combination of gemcitabine and carboplatin is well tolerated and active. Neutropenia was DLT. The observed activity matches that observable in cisplatin-gemcitabine studies, whereas duration of response and survival are even higher. A phase II trial is under way.  (+info)

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. (4/1928)

PURPOSE: To evaluate the efficacy of paclitaxel and carboplatin (PC) in small-cell lung cancer (SCLC) patients resistant to cyclophosphamide, doxorubicin, and etoposide (CDE). PATIENTS AND METHODS: We performed a phase II study with PC in SCLC patients who relapsed within 3 months after first-line treatment with CDE. Paclitaxel administration (175 mg/m2 by a 3-hour intravenous infusion) was followed by a 30-minute infusion of carboplatin (area under the curve 7; Chatelut formula) once every 3 weeks for five cycles. Dexamethasone, clemastine, and ranitidine were standard premedication before every cycle. RESULTS: Included were 35 patients (median age, 59 years; 16 with limited disease and 19 with extensive disease; Eastern Cooperative Oncology Group performance status of < or = 1; median time off treatment 6 weeks) who were previously treated with CDE (n = 33), oral etoposide (n = 2), and reinduction CDE (n = 15); only one patient had received three CDE treatments of five cycles. The CDE regimen was followed by local thoracic radiotherapy in seven patients. Hematologic toxicity of grade 3 or 4, for leukopenia was 27% and 6%, for thrombocytopenia 21% and 13%, and for anemia 17% and 0%, respectively, for a total of 132 cycles. Two patients had neutropenic fever; no toxic death occurred. Nonhematologic toxicity was paresthesia CTC grade 3, diarrhea grade 4, and myalgia grade 3 in one patient each. Reversible paresthesia (CTC grade 1 and 2) in toes and fingers was reported in 69% of patients. Thirty-four patients were assessable for response: complete response in two patients, partial response in 23 patients, stable disease in eight patients, and progressive disease in one patient (response rate, 73.5%; 95% confidence interval, 59% to 88%). One patient was found to have atypical carcinoid at pathologic review and was excluded. Median time to progression was 21 weeks (range, 3 to 40 weeks). Median survival was 31 weeks (range, 6 to 112 weeks). One-year survival was 9%. CONCLUSION: Second-line PC in CDE-resistant SCLC patients yields a high response rate and seems non-cross-resistant to CDE. Toxicity was mild in these poor-prognosis patients.  (+info)

Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. (5/1928)

PURPOSE: To determine the maximum-tolerated dose of paclitaxel with carboplatin with and without filgrastim support in patients with metastatic non-small-cell lung cancer (NSCLC) and to investigate the pharmacokinetics of paclitaxel and carboplatin and correlate these with the pharmacodynamic effects. PATIENTS AND METHODS: Thirty-six chemotherapy-naive patients with metastatic NSCLC were entered into this phase I dose-escalation and pharmacokinetic study. Paclitaxel was initially administered as a 24-hour infusion at a fixed dose of 135 mg/m2, and the carboplatin dose was escalated in cohorts of three patients, using Calvert's formula [dose(mg) = area under the concentration time curve (glomerular filtration rate + 25)], to target areas under the concentration time curve (AUCs) of 5, 7, 9, and 11 mg/mL x minute. A measured 24-hour urinary creatinine clearance was substituted for the glomerular filtration rate. Once the maximum-tolerated AUC (MTAUC) of carboplatin was reached, the paclitaxel dose was escalated to 175, 200, and 225 mg/m2. When the paclitaxel dose escalation began, the AUC of carboplatin was reduced to one level below the MTAUC. RESULTS: Myelosuppression was the major dose-limiting toxicity. Thrombocytopenia was observed at a carboplatin AUC of 11 mg/mL x minute after course 2 and thereafter. End-of-infusion plasma paclitaxel concentrations and median duration of time above 0.05 microM were similar in course 1 versus course 2 at the 135 and 175 mg/m2 dose levels. The neutropenia experienced by patients was consistent with that observed in patients who had received paclitaxel alone. Measured carboplatin AUCs were approximately 12% (20% v 3% with course 1 v course 2, respectively) below the desired target, with a standard deviation of 34% at all dose levels. A sigmoid-maximum effect model describing the relationship between relative thrombocytopenia and measured free platinum exposure indicated that patients who received the combination of carboplatin with paclitaxel experienced less severe thrombocytopenia than would be expected from carboplatin alone. Of the 36 patients entered onto the study, one experienced a complete response and 17 had partial responses, for an overall response rate of 50%. The recommended doses of paclitaxel (24-hour infusion) and carboplatin for future phase II studies of this combination are (1) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute without filgrastim support; (2) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 9 mg/mL x minute with filgrastim support; and (3) paclitaxel 225 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute with filgrastim support. CONCLUSION: The regimen of paclitaxel and carboplatin is well-tolerated and has promising activity in the treatment of NSCLC. There is no pharmacokinetic interaction between paclitaxel and carboplatin, but there is a pharmacodynamic, platelet-sparing effect on this dose-limiting toxicity of carboplatin.  (+info)

Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. (6/1928)

PURPOSE: An earlier phase II trial of paclitaxel in patients with metastatic nasopharyngeal carcinoma (NPC) demonstrated a response rate of 22%. Hence we proceeded to study the combination of paclitaxel and carboplatin in these patients. PATIENTS AND METHODS: The 21-day regimen was as follows: i.v. paclitaxel 175 mg/m2 over three hours preceded by standard premedications, followed by i.v. carboplatin dosed at AUC of six infused over one hour. Only chemotherapy-naive patients with histological diagnoses of undifferentiated carcinoma of the nasopharynx, systemic metastases and radiologically measurable lesions were eligible. RESULTS: Thirty-two patients were accrued to this study. Twenty patients (62%) had at least two sites of metastasis. The main grade 3-4 toxicity was neutropenia (31%). Nine patients (28%) developed neutropenic sepsis, which caused the demise of one of them. Twenty-four patients (75%) responded to treatment, with one (3%) attaining a complete response. The median time to progression of disease was seven months and the median survival was 12 months. At one year, 52% of the patients were alive. CONCLUSIONS: The combination of paclitaxel and carboplatin is an active regimen in NPC. Its convenience of administration and good tolerability make it an attractive alternative regimen to consider for patients with metastatic disease.  (+info)

Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience. Societe Francaise d'Oncologie Pediatrique. (7/1928)

Conventional therapy for intracranial germinomas is craniospinal irradiation. In 1990, the Societe Francaise d'Oncologie Pediatrique initiated a study combining chemotherapy (alternating courses of etoposide-carboplatin and etoposide-ifosfamide for a recommended total of four courses) with 40 Gy local irradiation for patients with localized germinomas. Metastatic patients were allocated to receive low-dose craniospinal radiotherapy. Fifty-seven patients were enrolled between 1990 and 1996. Forty-seven had biopsy-proven germinoma. Biopsy was not performed in ten patients (four had diagnostic tumour markers and in six the neurosurgeon felt biopsy was contraindicated). Fifty-one patients had localized disease, and six leptomeningeal dissemination. Seven patients had bifocal tumour. All but one patient received at least four courses of chemotherapy. Toxicity was mainly haematological. Patients with diabetus insipidus (n = 25) commonly developed electrolyte disturbances during chemotherapy. No patient developed tumour progression during chemotherapy. Fifty patients received local radiotherapy with a median dose of 40 Gy to the initial tumour volume. Six metastatic patients, and one patient with localized disease who stopped chemotherapy due to severe toxicity, received craniospinal radiotherapy. The median follow-up for the group was 42 months. Four patients relapsed 9, 10, 38 and 57 months after diagnosis. Three achieved second complete remission following salvage treatment with chemotherapy alone or chemo-radiotherapy. The estimated 3-year survival probability is 98% (CI: 86.6-99.7%) and the estimated 3-year event-free survival is 96.4% (CI: 86.2-99.1%). This study shows that excellent survival rates can be achieved by combining chemotherapy and local radiotherapy in patients with non-metastatic intracranial germinomas.  (+info)

1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. (8/1928)

The majority of men who die from prostate cancer (PC) have hormone-refractory disease. To date, chemotherapeutic agents have had little or no impact on the survival of such patients. To explore a new approach for the treatment of hormone-refractory PC, we examined the combination effects of cis- or carboplatin with vitamin D. 1alpha,25-Dihydroxyvitamin D3 (1alpha,25(OH)2D3) and its synthetic analogue, Ro 25-6760, have an antiproliferative effect on some prostate cancer cell lines. Consequently, the growth-inhibitory effects of the drugs were measured, both singularly and in combination with cis- or carboplatin, on PC cells. Our results show that although each of the drugs alone displayed antiproliferative activity, the growth inhibition of PC cells was further enhanced by the combination of 1alpha,25(OH)2D3 or Ro 25-6760 and either platinum agent. The greatest enhancement of inhibition occurred using smaller concentrations of the platinum compound in combination with higher concentrations of 1alpha,25(OH)2D3. Isobologram analysis revealed that 1alpha,25(OH)2D3 and platinum acted in a synergistic manner to inhibit the growth of PC cells. Our findings suggest that there is potential clinical value in combining 1alpha,25(OH)2D3 with platinum compounds for the treatment of advanced-stage human PC.  (+info)

TY - JOUR. T1 - Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma. T2 - A Japanese Gynecologic Oncology Group study (JGOG2041). AU - Nomura, H.. AU - Aoki, D.. AU - Takahashi, F.. AU - Katsumata, N.. AU - Watanabe, Y.. AU - Konishi, I.. AU - Jobo, T.. AU - Hatae, M.. AU - Hiura, M.. AU - Yaegashi, N.. N1 - Copyright: Copyright 2011 Elsevier B.V., All rights reserved.. PY - 2011/3. Y1 - 2011/3. N2 - Background: The purpose of this study is to assess the efficacy and safety of treatment with taxane plus platinum in combination therapies for advanced or recurrent endometrial carcinoma. Patients and methods: Patients with measurable disease derived from histologically confirmed stage III/IV or recurrent endometrial carcinoma were randomly assigned to receive docetaxel plus cisplatin (DP), docetaxel plus carboplatin (DC), or paclitaxel plus carboplatin (TC) every 3 ...
A comparison of biweekly combination chemotherapy (gemcitabine plus carboplatin) with weekly gemcitabine in elder patients (, 75) with previously untreated advanced non-small cell lung cancer. Primary objective is to determine the objective response rate (CR+PR by RECIST criteria) for biweekly gemcitabine and carboplatin combination chemotherapy versus weekly single gemcitabine as first-line therapy in elder advanced non-small lung cancer patients (, 76 years) who have received no prior treatment for non-small lung cancer. As secondary objectives, adverse event profile, tolerability of biweekly gemcitabine and carboplatin combination chemotherapy, progression-free survival and overall survival will be evaluated in both patients with biweekly gemcitabine and carboplatin combination chemotherapy and weekly single gemcitabine.. The study hypothesis is that biweekly combination chemotherapy of gemcitabine plus carboplatin may improve the efficacy. ...
Platinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This randomized phase II study was undertaken in order to compare the combination of carboplatin and pegylated liposomal doxorubicin (LD) with carboplatin and paclitaxel (CP) in this setting. Patients with histologically confirmed recurrent OC, at the time of or more than 6 months after platinum-based chemotherapy, were randomized to six cycles of CP (carboplatin AUC5 + paclitaxel 175 mg/m2, d1q21) or CLD (carboplatin AUC5 + pegylated LD 45 mg/m2, d1q28). A total of 189 eligible patients (CP 96, CLD 93), with a median age of 63 years, median Performance Status (PS) 0 and a median platinum free interval (PFI) of 16.5 months, entered the study. Discontinuation due to toxicity was higher in the CP patients (13.5% versus 3%, P = 0.016). The overall response rate was similar: CP 58% versus CLD 51%, P = 0.309 (Complete Response; CR 34% versus 23%) and there was no statistical difference in time-to
OBJECTIVES: To evaluate the efficacy of combination of navitoclax, carboplatin and paclitaxel in ovarian cancer.. METHODS: 8 ovarian cancer cell lines were treated with either doublet or triplet combinations of navitoclax, carboplatin and paclitaxel. Interactions were assessed by determining a combination index or measuring caspase activity. The effect of the combinations was also evaluated by measuring the inhibition of cells grown as spheroids.. RESULTS: Navitoclax exhibited modest (IC(50)=3-8 μM) single agent potency. Antagonism between carboplatin and paclitaxel was evident in Ovcar-4, Ovcar-8 and Skov-3 cells. Drug combinations including navitoclax with carboplatin and/or paclitaxel showed significantly less antagonism, or even synergy, in several cell lines than carboplatin/paclitaxel alone. Navitoclax enhanced the activation of caspase 3/7 induced by carboplatin and/or paclitaxel in Igrov-1 cells. Combinations of navitoclax, carboplatin and paclitaxel showed more than additive activity ...
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Particpants will be randomized to receive 4 cycles of carboplatin (C)/paclitaxel (P) and either pictilisib or placebo, with (participants with non-squamous NSCLC) or without (participants with squamous NSCLC) bevacizumab (B). Anticipated time on study treatment is until disease progression or intolerable toxicity occurs. Participants in placebo arms with disease progression may cross over to open-label active pictilisib ...
Looking for online definition of Paclitaxel/Carboplatin or what Paclitaxel/Carboplatin stands for? Paclitaxel/Carboplatin is listed in the Worlds largest and most authoritative dictionary database of abbreviations and acronyms
An analysis of the GeparSixto trial in triple-negative breast cancer showed that adding carboplatin to neoadjuvant therapy improved pathologic complete response rate in patients without BRCA1/2 mutation and that response rates were higher overall in those with mutations, without additive effects observed for carboplatin. The analysis was reported by Hahnen et al in JAMA Oncology. GeparSixto showed the addition of neoadjuvant carboplatin to anthracycline, taxane, and bevacizumab (Avastin) increased pathologic complete response rates among all patients.. Study Details The current analysis included 291 patients, of whom 146 received carboplatin. Pathogenic BRCA1 and BRCA2 germline mutations were present in 50 patients (17.2%), including 26 patients who received carboplatin and 24 patients who did not.. Pathologic Complete Response Rate. The pathologic complete response rate was 56.8% in the carboplatin group vs 41.4% in the group that did not receive carboplatin (odds ratio [OR] = 1.87, P = .009). ...
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC ...
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC ...
TY - JOUR. T1 - Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. AU - Xiong, Xiaoxiong. AU - Sui, Meihua. AU - Fan, Weimin. AU - Kraft, Andrew S.. N1 - Funding Information: This work was supported in part by NIH grant and CA92280 (to W.F.).. PY - 2007/7. Y1 - 2007/7. N2 - The combination of carboplatin and paclitaxel is widely used to treat multiple solid tumors including ovarian, lung and breast cancer. Usually these drugs are given simultaneously with little regard to the importance of scheduling to obtain a maximal response. To investigate the importance of sequencing, the human breast Bcap37 and ovarian OV2008 cancer cell lines were exposed to carboplatin and paclitaxel in three different sequences: (1) pretreatment with paclitaxel followed by carboplatin, (2) pretreatment of carboplatin followed by paclitaxel and (3) simultaneous treatment with these two agents. The combination of carboplatin and paclitaxel resulted in antagonistic ...
View more ,Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alternatively, nCRT with cisplatin plus fluorouracil (CF) can be used. Definitive chemoradiotherapy (dCRT) with CP or CF can be used if surgery is not planned. In the absence of comparative trials, we aimed to evaluate outcomes of CP and CF in the settings of TMT and dCRT. Methods: A single-site, retrospective cohort study was conducted at the Princess Margaret Cancer Centre to identify all patients who received CRT for locoregional esophageal or GEJ cancer. Overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method and multivariable Cox regression model. The inverse probability treatment weighting (IPTW) method was used for sensitivity analysis. Results: Between 2011 and 2015, 93 patients with esophageal ...
To report the results of combined chemoradiation (CCRT) with cisplatin versus carboplatin in locally advanced cervical carcinoma. From 2009 to 2013, 255 patients with stage IIB-IVA cervical carcinoma, according to FIGO staging were prospectively assigned to be treated with pelvic radiotherapy followed by brachytherapy given concurrently with cisplatin or carboplatin in the treatment of locally advanced cervical cancer. Treatment outcomes and toxicitiy were evaluated. Two-hundred and thirteen patients could be evaluated. At a median follow-up time of 43 months (6-69 months), the 3-year local control, disease-free survival, metastasis-free survival and overall survival rates were 93, 80.8, 85.0 and 87.3 %, respectively. No statistical difference in terms of local control, disease-free survival, metastasis-free survival and overall survival rates between cisplatin and carboplatin treatments was observed in this study. Eighty-six percents of the patients in the carboplatin group could receive more than 4
The combination of carboplatin-paclitaxel is a global standard following recent consensus recommendations [20, 4]. Although this treatment is highly effective, most patients recur. The majority are platinum-sensitive at first relapse, thus, candidates for re-treatment with platinum. Indeed, these patients will be generally re-treated with a platinum-taxane combination, especially in the light of recent trials showing advantage over platinum monotherapy [9]. However, the cumulative neurotoxicity of both drugs, as well as the increased risk of neurotoxicity for patients in relapse and the further experience of alopecia, are essential considerations when selecting second-line therapy [21]. As treatment at relapse is rarely curative, toxicity, tolerance, ease of administration and QoL should be interrelated to efficacy and survival prolongation when novel platinum-based combinations are evaluated for patients with platinum-sensitive OC.. This study was originally designed in 1999, in an era when ...
Materials and methods The overall number of patients and carboplatin courses, sex, age, diagnosis and percentage overdose were extracted from the Farmis database on cytostatics management, from January 2011 to September 2013. Overdoses were designated: carboplatin dosing ,900 mg for a target AUC = 6; carboplatin dosing ,750 mg for a target AUC = 5; carboplatin dosing ,600 mg for a target AUC = 4. In the event of overdosing (Common Terminology Criteria for Adverse Events (CTCAE) criteria), blood tests were sought before the next round of treatment and the need to delay the chemotherapy treatment were evaluated.. ...
Patients and Methods Six hundred sixty-seven patients with stage I to IV CCC of the ovary were randomly assigned to receive irinotecan 60 mg/m2 on days 1, 8, and 15 plus cisplatin 60 mg/m2 on day 1 (CPT-P group) every 4 weeks for six cycles or paclitaxel 175 mg/m2 plus carboplatin area under the curve 6.0 mg/mL/min on day 1 every 3 weeks for six cycles (TC group). The primary end point was progression-free survival. Secondary end points were overall survival, overall response rate, and adverse events ...
The UK Medical Research Council conducted this trial of carboplatin chemotherapy in advanced seminoma to compare single agent carboplatin with a standard combination of etoposide with cisplatin. The use of single agent carboplatin was expected to be associated with reduced toxicity. A total of 130 patients with advanced seminoma were randomly assigned to treatment with either single agent carboplatin (C) at a dose of 400 mg/m(2)to be corrected for glomerular filtration rate outside the range 81-120 ml min(-1)and to be administered on day 1 of a 21 day cycle to a total of 4 cycles or to etoposide + platinum (EP). The trial was designed as an equivalence study aiming to exclude a reduction in the 3-year progression-free survival in patients allocated to carboplatin of between 10 and 15%, requiring initially a target accrual of 250 patients (90% power significance level 5% (one-sided)). The trial closed after 130 patients had been randomized following recommendation by an independent data ...
TY - JOUR. T1 - Paclitaxel plus carboplatin. T2 - An effective combination chemotherapy for advanced non-small-cell lung cancer or just another elvis sighting?. AU - Johnson, D. H.. AU - Einhorn, L. H.. PY - 1995/1/1. Y1 - 1995/1/1. UR - UR - U2 - 10.1200/JCO.1995.13.8.1840. DO - 10.1200/JCO.1995.13.8.1840. M3 - Editorial. C2 - 7636526. AN - SCOPUS:0029130242. VL - 13. SP - 1840. EP - 1842. JO - Journal of Clinical Oncology. JF - Journal of Clinical Oncology. SN - 0732-183X. IS - 8. ER - ...
Chemotherapies are associated with significant inter-individual variability in therapeutic effect and adverse drug reactions. In lung cancer the use of gemcitabine and carboplatin induces grade 3-4 myelosuppression in about ¼ of the patients while an equal fraction of patients are basically unaffected in terms of myelosuppressive side effects. We therefore set out to try to identify genetic markers for gemcitabine / carboplatin induced myelosuppression. We selected 32 patients that suffered extremely high neutropenia and thrombocytopenia (grade 3 or 4 after first chemotherapy cycle) or were virtually unaffected (grade 0-1 after the first chemotherapy cycle) by the chemotherapy out of 243 lung cancer patients treated with gemcitabine / carboplatin. These patients were exome sequenced and their genetic differences compared using six different bioinformatic strategies; whole exome non-synonymous SNV association analysis, deviation from Hardy-Weinberg equilibrium, analysis of genes selected by a ...
LOS ANGELES--Interim analysis of a major German-Austrian trial comparing cisplatin (Platinol)/paclitaxel (Taxol) with carboplatin (Paraplatin)/paclitaxel as first-line treatment in ovarian cancer found significantly less toxicity with carboplatin/paclitaxel, with no apparent loss of efficacy. 1
We have previously reported on bilateral intra-arterial (IA) chemosurgery for bilateral retinoblastoma, or tandem therapy.1 While this allows both eyes to be treated during the same IA session, it also exposes the patient to twice the dose of chemotherapy (typically melphalan and topotecan). Even at the doses used for IA, the systemic levels of melphalan can be dose-limiting (melphalan may induce neutropenia at doses higher than 0.4 mg/kg). To obviate the need for melphalan dose restriction during tandem therapy, we report on the use of single agent carboplatin to the fellow eye. ...
TY - JOUR. T1 - A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma. T2 - A Gynecologic Oncology Group Study. AU - Mannel, Robert S.. AU - Brady, Mark F.. AU - Kohn, Elise C.. AU - Hanjani, Parviz. AU - Hiura, Masamichi. AU - Lee, Roger. AU - DeGeest, Koen. AU - Cohn, David E.. AU - Monk, Bradley J.. AU - Michael, Helen. PY - 2011/7/1. Y1 - 2011/7/1. N2 - Objective: To compare the recurrence-free interval (RFI) and safety profile in patients with completely resected high-risk early-stage ovarian cancer treated with intravenous (IV) carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24 weeks. Methods: Eligibility was limited to patients with stage IA/B (grade 3 or clear cell), all IC or II epithelial ovarian cancer. All patients were to receive carboplatin AUC 6 and paclitaxel 175 mg/m2 q3 weeks × 3 courses with random assignment ...
TY - JOUR. T1 - Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. AU - Lara, Primo N. AU - Douillard, Jean Yves. AU - Nakagawa, Kazuhiko. AU - Von Pawel, Joachim. AU - McKeage, Mark J.. AU - Albert, Istvan. AU - Losonczy, Gyor̈gy. AU - Reck, Martin. AU - Heo, Dae Seog. AU - Fan, Xiaolin. AU - Fandi, Abderrahim. AU - Scagliotti, Giorgio. PY - 2011/8/1. Y1 - 2011/8/1. N2 - Purpose: This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non-small-cell lung cancer (NSCLC) versus chemotherapy alone. Patients and Methods: Patients with advanced stage IIIB or IV NSCLC, stratified by sex and tumor histology, were randomly assigned 1:1 to paclitaxel (200 mg/m2) and carboplatin (area under the curve, 6.0) with or without ...
TY - JOUR. T1 - Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small-cell lung cancer. T2 - A systematic review. AU - Steuer, Conor E.. AU - Behera, Madhusmita. AU - Ernani, Vinicius. AU - Higgins, Kristin A.. AU - Saba, Nabil F.. AU - Shin, Dong M.. AU - Pakkala, Suchita. AU - Pillai, Rathi N.. AU - Owonikoko, Taofeek K.. AU - Curran, Walter J.. AU - Belani, Chandra P.. AU - Khuri, Fadlo R.. AU - Ramalingam, Suresh S.. PY - 2017/8. Y1 - 2017/8. N2 - IMPORTANCE: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. There are no prospective comparisons of these 2 regimens in this setting. OBJECTIVE: To conduct a systematic review of published trials to compare outcomes and toxic effects between cisplatin-etoposide and carboplatin-paclitaxel in ...
Fingerprint Dive into the research topics of Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study. Together they form a unique fingerprint. ...
Background AMG 386, an investigational peptibody, blocks the interaction of angiopoietin-1 and -2 with the Tie2 receptor, thereby inhibiting tumor angiogenesis. We evaluated the tolerability of AMG 386 plus paclitaxel and carboplatin in ovarian cancer patients who had primary or interval debulking surgery (PDS or IDS, respectively).. Methods Women (≥ 18 yrs, GOG ≤ 1) with high-risk stage I (grade 3 or aneuploid grade 1 or 2) or II-IV ovarian cancer received 6 cycles of the combination AMG 386 (15 mg/kg IV QW) plus paclitaxel (175 mg/m2 IV Q3W) and carboplatin (AUC 6 IV Q3W) followed by AMG 386 maintenance monotherapy up to 18 months. Patients had PDS; patients with disease stage IIIC or IV had the option of planned IDS. AMG 386 dosing was withheld for > 4 weeks after PDS or before IDS. The primary endpoint was the incidence of dose-limiting toxicities (DLTs), which determined cohort expansion to n = 25; secondary endpoints included the patient incidence of adverse events (AEs), the incidence ...
The use of weekly chemotherapy for the treatment of patients with advanced-stage serous-type epithelial Tubo-ovarian cancer (ETOC), and primary peritoneal serous carcinoma (PPSC) is acceptable as the front-line postoperative chemotherapy after primary cytoreductive surgery (PCS). The main component of dose-dense chemotherapy is weekly paclitaxel (80 mg/m2), but it would be interesting to know what is the difference between combination of triweekly cisplatin (20 mg/m2) or triweekly carboplatin (carboplatin area under the curve 5-7 mg/mL per min [AUC 5-7]) in the dose-dense paclitaxel regimen. Therefore, we compared the outcomes of women with Gynecology and Obstetrics (FIGO) stage IIIC ETOC and PPSC treated with PCS and a subsequent combination of dose-dense weekly paclitaxel and triweekly cisplatin (paclitaxel–cisplatin) or triweekly carboplatin using AUC 5 (paclitaxel–carboplatin). Between January 2010 and December 2016, 40 women with International Federation of Gynecology and Obstetrics
Fingerprint Dive into the research topics of Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study. Together they form a unique fingerprint. ...
Rare Cancer News & Clinical Trials » Trial - Sarcoma » Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or ...
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced continued encouraging results in an ongoing Massachusetts General Hospital Cancer Center and Dana-Farber/Harvard Cancer Center (DF/HCC) Phase 2 trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients. Fifteen patients have now been enrolled and, to date, 60% (9) have had slower than expected disease progression. NOV-002 was well-tolerated, further extending the excellent safety profile NOV-002 has demonstrated in previous studies. Detailed results of this trial will be presented as a poster at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO) taking place May 30 - June 3 in Chicago, Illinois.. I am encouraged by these results in platinum-resistant ovarian cancer, with NOV-002 (in combination with carboplatin) apparently slowing disease progression in over half of the ...
Background: This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and oral rucaparib, a poly (ADP-ribose) polymerase inhibitor, combined with chemotherapy in patients with advanced solid tumours. Methods: Initially, patients received escalating doses of intravenous rucaparib combined with carboplatin, carboplatin/paclitaxel, cisplatin/pemetrexed, or epirubicin/cyclophosphamide. Subsequently, the study was amended to focus on oral rucaparib (once daily, days 1-14) combined with carboplatin (day 1) in 21-day cycles. Doselimiting toxicities (DLTs) were assessed in cycle 1 and safety in all cycles. Results: Eighty-five patients were enrolled (22 breast, 15 ovarian/peritoneal, 48 other primary cancers), with a median of three prior therapies (range, 1-7). Neutropenia (27.1%) and thrombocytopenia (18.8%) were the most common grade ≥3 toxicities across combinations and were DLTs with the oral rucaparib/carboplatin combination. Maximum tolerated dose for the combination was 240
This study is investigating whether the addition of another drug, Amifostine, can reduce the side effects of current combination treatment (radiation and
Marty - Youre right...on the time difference. Like you, the bigger doses during the nine weeks took anywhere from 6 - 8+ hours with all of the additional solutions and only one chemo at a time.. The Carboplatin usually only took an hour or so. The day I had chemo, Id also go down and do the rads after.. Well, Id get the Amifostine injection in the tummy first, then rads. Amifostine injection and rads every day for seven weeks....uggg.. Pat - about the only side effect I did have during the Cisplatin, Taxotere and 5FU was I lost my hair (all hair) around week 3 - 4, then it starting growing back within a few weeks.. When I started the Carboplatin, the hair was already back, though really fine an just like first hair...LOL, it was kind of humorous.. Well, thinking back, I did also lose all of my toe nails (a little weird) my finger nails became really brittle also. I also initially had hiccups frequently, and my potassium dropped, had to have extra for 10 days once.. JG ...
A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-pd-l1 antibody) in combination with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-based therapy
To determine the maximum-tolerated dose and the recommended dose of radiation and carboplatin and pemetrexed in locally advanced non-small cell lung cancer.
TY - JOUR. T1 - Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer. T2 - a phase 3, open-label, randomised controlled trial. AU - Katsumata, Noriyuki. AU - Yasuda, Makoto. AU - Takahashi, Fumiaki. AU - Isonishi, Seiji. AU - Jobo, Toshiko. AU - Aoki, Daisuke. AU - Tsuda, Hiroshi. AU - Sugiyama, Toru. AU - Kodama, Shoji. AU - Kimura, Eizo. AU - Ochiai, Kazunori. AU - Noda, Kiichiro. N1 - Funding Information: SI and DA have received honoraria from Bristol-Myers Squibb. DA and HT have received grant support from Bristol-Myers Squibb. All other authors declare that they have no conflicts of interest. Funding Information: This study was funded by an unrestricted grant from Bristol-Myers Squibb. We thank the women who participated in this trial and Akihiro Yanagisawa, Kei Matsubara for assisting protocol design and review, Keiichi Fujiwara for internal auditing, and Robert F Ozols for protocol design and manuscript review. PY - 2009. Y1 - ...
TY - JOUR. T1 - Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer. T2 - Preliminary results comparing sequential phase II trials. AU - DeVore, R. F.. AU - Jagasia, M.. AU - Johnson, D. H.. PY - 1997/10/22. Y1 - 1997/10/22. N2 - Our group previously described the activity of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (given as a 24-hour infusion) in 51 patients with advanced non-small cell lung cancer. To facilitate outpatient administration, the regimen was modified to infuse paclitaxel over 1 hour. Between February 1995 and August 1996, 63 patients with advanced non-small cell lung cancer were accrued by the Vanderbilt Cancer Center and its affiliate network. The first four patients received paclitaxel 175 mg/ml2; all subsequent patients received paclitaxel 200 mg/m2. The carboplatin dose was determined using the Calvert formula, with a target area under the concentration-time curve of 6. ...
TY - JOUR. T1 - Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. AU - Lemma, Girum L.. AU - Lee, Ju Whei. AU - Aisner, Seena C.. AU - Langer, Corey J.. AU - Tester, William J.. AU - Johnson, David H.. AU - Loehrer, Patrick J.. PY - 2011/5/20. Y1 - 2011/5/20. N2 - Purpose: The purpose of this study was to evaluate the impact of carboplatin and paclitaxel in patients with advanced previously untreated thymoma and thymic carcinoma. Patients and Methods We conducted a prospective multicenter study in patients with unresectable thymoma (n = 21) or thymic carcinoma (n = 23). Patients were treated with carboplatin (area under the curve, 6) plus paclitaxel (225 mg/m2) every 3 weeks for a maximum of six cycles. The primary end point of this trial was to evaluate the objective response rate. Results: From February 2001 through January 2008, 46 patients were enrolled. Thirteen patients had grade 4 or greater toxicity, mostly neutropenia. Using RECIST (Response ...
Japans largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
Scientists at Dana-Farber Cancer Institute have shown that experimental diabetes drugs can make cancer cells more vulnerable to traditional chemotherapy agents, and they say such combinations should be explored to potentially improve outcomes for cancer patients.. Reporting in the Proceedings of the National Academy of Sciences, investigators demonstrated in cancer cell lines and animal models that the research compounds - similar to common anti-diabetic agents known as thiazolidinediones (TZDs) - sensitized lung tumor cells to carboplatin chemotherapy. Tumors in rodents treated with the combination of carboplatin and one of the experimental compounds, SR1664, weighed less than those in animals treated with carboplatin alone.. The research also showed that the combination sensitized triple-negative breast cancer cells in the laboratory, causing them to self-destruct. However, not all types of cancer cells appear to be made vulnerable to chemotherapy combined with the experimental compounds, the ...
The addition of bevacizumab (Avastin) to gemcitabine and carboplatin, followed by bevacizumab until disease progression, resulted in significantly improved progression-free survival compared to gemcitabine and carboplatin plus placebo among women with platinum-sensitive recurrent ovarian, primary periotoneal, or fallopian tube cancer. Results from the phase III OCEANS (Ovarian Cancer Study Comparing the Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum-Sensitive Recurrent Disease) trial were published in the Journal of Clinical Oncology.1 The study was sponsored by Genentech, which manufactures bevacizumab.. Analysis of Progression-free Survival. Both treatment groups consisted of 242 patients with histologically confirmed disease progression and ≥ 6 months after completion of front-line platinum-based chemotherapy. At the time of the final [progression-free survival] analysis (338 events), the median follow-up was 24 months, the authors reported. The median ...
Jonathan Goldman, MD explains IMFINZI is the first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer._______In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backboneAstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing IMFINZI® (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC). IMFINZI in combination with four cycles of standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) demonstrated a statistically-significant and clinically-meaningful improvement in OS vs. SoC chemotherapy consisting of up to six cycles of chemotherapy and optional prophylactic cranial irradiation (PCI). The risk of death was reduced by 27% (equal to a hazard ratio of 0.73), with median OS of 13.0 months for
The meta-analysis of data from 53 studies including 6,885 patients with stage III-IV epithelial ovarian cancer who underwent cytoreductive surgery followed by cisplatin or carboplatin-based chemotherapy showed that percent maximal cytoreduction was an independent prognostic variable for survival (P ,0.001) [2]. Each 10% increase in maximal cytoreduction was associated with a 5.5% increase in median survival. It is noteworthy that median survival time was 23.0 months for patients who had maximal cytoreductive surgery rate of 25% or less compared to 36.8 months for those in which maximal cytoreductive surgery was achieved in more than 75% of cases. The present study confirms that optimal surgical cytoreduction is the most important prognostic factor for advanced epithelial ovarian cancer [2-5, 7, 10, 17]. All attempts should be made to achieve complete cytoreduction, but when this result is not achievable, the surgical goal should be al least a residual disease , 1 cm [7]. Optimal cytoreduction ...
This randomized phase II trial studies paclitaxel and carboplatin to see how well they work compared with bleomycin sulfate, etoposide phosphate, and cisplatin in treating patients with sex cord-ovarian stromal tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has returned (recurrent). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating sex cord-ovarian stromal tumors. ...
Amifostine protects normal tissue from the cytotoxic damage induced by radiation and chemotherapy. in this study. 39 consecutive newly diagnosed children with osteosarcoma were assessed; 20 received amifostine and 19 did not. the chemotherapy regimen included an induction phase of three cycles of cisplatin (100 mg/m(2)), carboplatin (500 mg/m(2)), and doxorubicin (60 mg/m(2)), followed by surgery. Alternating cycles of cisplatin/ifosfamide (9 mg/m(2)), ifosfamide/doxorubicin. carboplatin/doxorubicin, and ifosfamide/carboplatin were administered every 3 weeks to complete 26 weeks of treatment. Amifostine was administered 15 minutes before the infusions of cisplatin and carboplatin in a total of 193 infusions. Side effects during infusions and renal, hearing, and bone marrow toxicities were evaluated and compared between the two groups. Hypotension was observed in 28 (14.5%) infusions. No patient required discontinuation of therapy. Fewer than two episodes of vomiting occurred in 130 (71%) ...
Clinical trial for Recurrent Thymic Carcinoma | Locally Advanced Thymic Carcinoma | Unresectable Thymic Carcinoma | Metastatic Thymic Carcinoma , Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced Recurrent or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
Package insert & quality information about side effects from cancer-pharmacist experts on Non-Small Cell Lung Cancer (NSCLC) | Carboplatin + Abraxane
Forty-nine trials involving 8763 women were included. The data were combined to calculate hazard ratios (HR) for survival on an intention-to-treat basis. For single non-platinum versus platinum combination chemotherapy the overall HR for survival was 0.93, 95% confidence interval (CI) 0.83 to1.05 favouring platinum-based combination chemotherapy. For non-platinum regimens compared with the same regimen plus cisplatin the survival HR was 0.88, 95% CI 0.79 to 0.98 in favour of adding platinum to drug regimens. Single platinum compared with platinum combination gave a HR of 0.91, 95% CI 0.79 to 1.05 favouring combination chemotherapy. Cisplatin versus carboplatin gave a HR of 1.02, 95% CI 0.93 to 1.12. Sub-group analyses for age, stage, grade, histology, resection, bulk of residual tumour and performance status were undertaken for cisplatin versus carboplatin only. No difference in effect was found. ...
Squamous cell carcinomas of the oral mucosa are known to be very aggressive and often very frustrating in their therapy. Does this combination of carboplatin and piroxicam coming from human medicine offer better therapeutic results than the current therapies? At least the preliminary results seems to be promising!
Here we provide evidence to get an inherent function for Arpc1b, an element from the Arp2/3 complex, in regulation of mitosis and demonstrate that its depletion inhibits Aurora A activation on the centrosome and impairs the power of mammalian cells to enter mitosis. (Marumoto et al., 2005). Association of Aurora A with centrosomes, spindle poles, aster microtubules, as well as the midbody facilitates its function in regulating centrosome maturation, duplication, Carboplatin kinase activity assay and cell routine progression, which are often affected and dysregulated in the lack of Aurora A (Katayama et al., 2003). Lack of Aurora A in embryonic mice is normally lethal because of flaws in mitotic spindle set up and misaligned and lagging chromosomes (Sasai et al., 2008). On the other hand, Aurora A up-regulation promotes centrosome amplification, aneuploidy, and cancers, and Aurora kinase appearance is normally often elevated in lots of cancer tumor types (Katayama et al., 2003). The paramount ...
TY - JOUR. T1 - Novel separation method for highly sensitive speciation of cancerostatic platinum compounds by HPLC-ICP-MS. AU - Hann, S.. AU - Stefánka, Zs. AU - Lenz, K.. AU - Stingeder, G.. PY - 2005/1/1. Y1 - 2005/1/1. N2 - A high-performance liquid chromatography-inductively coupled plasma mass spectrometry (HPLC ICP-MS) method is presented for analysis of cisplatin, monoaquacisplatin, diaquacisplatin, carboplatin, and oxaliplatin in biological and environmental samples. Chromatographic separation was achieved on pentafluorophenylpropyl-functionalized silica gel. For cisplatin, carboplatin, and oxaliplatin limits of detection of 0.09, 0.10, and 0.15 μg L -1, respectively, were calculated at m/z 194, using aqueous standard solutions. (3 μL injection volume). The method was utilized for model experiments studying the stability of carboplatin and oxaliplatin at different chloride concentrations simulating wastewater and surface water conditions. It was found that a high fraction of ...
Hi Terry,. Im sorry to hear about your daughter. I did carbo/taxol every three weeks for three rounds. I did not find that it was so unbearable, I seemed to tolerate it fairly well. What are your daughters complaints with the side effects? Nausea/vomiting may mean she needs to try a different anti-nausea med. There are also appetite stimulants that can be prescribed. If the bone/joint pain was an issue try L-Glutamine poweder three times a day, movement/walking/stretching, and make sure that her doctor is aware of her discomfort so that he can authorize appropriate pain relief for her.. Carbo/taxol, as far as I know, does not cause damage to hearing or sight. Cisplatin is known to cause hearing loss, which is similar to carboplatin, but carboplatin is much less likely to cause hearing loss. Carboplatin also is less likely to damage kidney than cisplatin though I beleive it causes more myelosuppression. I hope she is feeling better soon. I know she is strong and can make it through the treatment. ...
There were no toxic deaths in either the infusional or fractionated ICE studies. The toxicities in the infusional studyr are not fully described but the same group also published a study of ICE salvage in 163 patients with non-Hodgkin lymphoma.r In this group, thrombocytopenia was the dose limiting toxicity with grade 3/4 thrombocytopenia occurring in 29% of cycles given and 30% of patients requiring platelet transfusion. 13% of cycles were complicated by grade 4 neutropenia requiring hospital admission. The neutrophil nadir occurred 7 to 9 days after the beginning of the cycle. Anaemia was a common occurrence with 98 patients requiring red cell transfusions. Non-haematological toxicities were uncommon and included gross haematuria in 4 of 381 cycles, one case of reversible nephrotoxicity, two cardiac toxicities (congestive cardiac failure & supraventricular tachycardia) and 5 cases of neurological toxicity (1 peripheral neuropathy and 4 confusion due to ifosfamide-induced encephalopathy). The ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations.. This Tecentriq regimen has demonstrated a significant survival benefit in the initial treatment of metastatic non-squamous non-small cell lung cancer, said Sandra Horning, MD, Roches Chief Medical Officer and Head of Global Product Development. Todays approval supports our combination approach for Tecentriq in lung cancer and our vision to develop medicines that improve outcomes for patients with this complex disease.. This approval is based on results from the Phase III IMpower150 study, which showed that Tecentriq in combination with Avastin and chemotherapy helped people live significantly longer, compared to ...
article{3574ec13-af1d-46ee-a05a-eaab584bbe9e, abstract = {Background: The purpose was to investigate adjuvant marrow-supportive high-dose chemotherapy compared with an equitoxicity-tailored comparator arm. Patients and methods: Five hundred and twenty-five women below the age of 60 years with operated high-risk primary breast cancer were randomised to nine cycles of granulocyte colony-stimulating factor supported and individually tailored FEC (5-fluorouracil, epirubicin, cyclophosphamide), (n = 251) or standard FEC followed by marrow-supported high-dose therapy with CTCb (cyclophosphamide, thiotepa, carboplatin) therapy (n = 274), followed by locoregional radiotherapy and tamoxifen for 5 years. Results: There were 104 breast cancer relapses in the tailored FEC group versus 139 in the CTCb group (double triangular method by Whitehead, P = 0.046), with a median follow-up of all included patients of 60.8 months. The event-free survival demonstrated 121 and 150 events in the tailored FEC- and CTCb ...
N Engl J Med. 2009 Aug 19; Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka MBACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer. METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calculated to produce an area under the curve of 5 or 6 mg per milliliter per minute) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients). The primary end point was progression-free survival. RESULTS: The 12-month rates of progression-free survival were 24.9% with gefitinib and 6.7% with ...
Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib. ( number, N …
GOG 175 - Ovary - A Randomized Phase III Trial Of IV Carboplatin (AUC 6) and Paclitaxel 175 MG/M2 Q 21 Days X 3 Courses Plus Low-Dose Paclitaxel 40 MG/M2 Weekly VS. Carboplatin (AUC 6) and Paclitaxel 175MG/M2 Q21 Days X 3 Courses in Patients With Early Stage Ovarian ...
Clinical Trials - This is a multi-institutional Phase I dose-escalation and dose-expansion trial for patients with advanced, solid tumor mali...
Title. Comparing the Effectiveness of Different Drug Combinations for Advanced Cancer of the Urothelium Which Cannot Be Controlled With Surgery (A Phase III Trial). Sponsor. Eastern Cooperative Oncology Group through the NCI-sponsored Cancer Cooperative Group Program. Purpose of the Study. To slow, stop or decrease the growth of cancer of the urothelium and to compare and evaluate the effectiveness of the two drug treatments. The two treatments were; 1) a Two-Drug (paclitaxel and carboplatin) Combination Chemotherapy, and 2) a Four-Drug (methotrexate, vinblastine, asplatin, doxorubin) Combination Chemotherapy. The urothelium is the lining of the kidney, ureter, bladder, or lining of the urinary tract.. Results. The study did not show one treatment to be more beneficial than the other. Of patients receiving the four-drug combination, 12.8 percent experienced a complete response rate (no detectable cancer remaining) and 23.1 percent experienced a decrease in the size or extent of their cancer ...
Inclusion/exclusion criteria. Requirements for enrollment in the trial included histologic proof of advanced solid tumor malignancy with no hope of curative, or clearly established life-prolonging, therapy; age ,18 years; performance status 0 to 2; life expectancy ,3 months; ability to accomplish informed consent; WBC ,3,500; ANC ,1,700; PLT ,100,000; normal direct bilirubin; and creatinine, alkaline phosphotase, aspartate aminotransferase, and alanine aminotransferase ,2.5× UNL. Exclusion criteria included radiation to ,25% bone marrow, prior cisplatin or carboplatin therapy; chemotherapy, biological, immunotherapy, or radiotherapy within the past 4 weeks (6 weeks for mitomycin C/nitrosoureas); New York Heart Association class III or IV or history of angina; central nervous system metastases or seizure disorder; pregnancy/lactation; and grade ,1 peripheral neuropathy.. Treatment cohorts and schedules. Patients were enrolled in three sequential cohorts. In cohort/stage I, cisplatin was fixed at ...
"Carboplatin dosing". Center for Drug Evaluation and Research. Archived from the original on 2011-11-19. Harita N, Hayashi T, ... new FDA guidelines have suggested limiting doses to specified maxima with carboplatin, a chemotherapy drug. A 2009 Japanese ...
Others include carboplatin and oxaliplatin. These compounds are capable of crosslinking DNA, and kill cells by similar pathways ... Compounds containing platinum, such as cisplatin, oxaliplatin and carboplatin, are applied in chemotherapy against certain ...
... carboplatin, etoposide). Cutaneous ALCL is typically treated by surgical excision and radiation. The prognosis varies according ...
p. 9. "Carboplatin: Chemistry for Fighting Cancer". Johnson Matthey. "Scientific Symposium on Paraplatin" (PDF). Platinum ... A blue plaque commemorating the work of the Institute for Cancer Research, including the discovery of Carboplatin, was erected ... JM8 was identified and successfully launched as Carboplatin (Paraplatin) by Bristol Myers Squibb in 1986. This achievement was ... He is credited with the discovery of Carboplatin, JM 216 (Satraplatin), and AMD 473. A collaboration with Johnson Matthey ...
This has no effect on carboplatin. It also increases the AUC of docetaxel, doxorubicin and irinotecan but decreases the AUC of ... Plasma concentration of sorafenib and paclitaxel may be increased when the drugs are co-administered along with carboplatin. ... is used as a first-line treatment in combination with paclitaxel and carboplatin. It can also be used in the treatment for ... of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian ...
Carboplatin Dicycloplatin "Cisplatin Use During Pregnancy". 12 September 2019. Retrieved 25 February 2020. " ...
Cisplatin and etoposide, Carboplatin and etoposide. The drug paclitaxel may be useful in the treatment of cisplatin-resistant ... In this study, patients with ES-SCLC were treated with standard carboplatin plus etoposide and were randomized to receive ... vincristine and carboplatin. Response rates are high even in extensive disease, with between 15% and 30% of subjects having a ... "Combination therapy with carboplatin and paclitaxel for small cell lung cancer". Respiratory Investigation. 57 (1): 34-39. doi: ...
carboplatin/ paclitaxel as a first-line treatment in advanced NSCLC. IPASS studied 1,217 patients with confirmed adenocarcinoma ... September 2009). "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma". The New England Journal of Medicine. 361 ( ... September 2009). "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma". The New England Journal of Medicine. 361 ( ...
Bone marrow suppression is the dose-limiting toxicity of carboplatin. Carboplatin is much less damaging to kidneys compared to ... Carboplatin Carboplatin, like cisplatin, is composed of a central atom of platinum and two ammonia molecules, but it has a ... December 2006). "Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer". New England Journal of ... These two studies made significant impact on the chemotherapy choices for treating NSCLC, with cisplatin or carboplatin as the ...
In March 2019, it was approved in the United States, in combination with carboplatin and etoposide, for the first-line ... "FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations". U.S. Food and ... The chemotherapy used was Carboplatin, and Paclitaxel. Median overall survival was 19.8 and 14.9 months for patients treated ... IMpower130 was an open-label, phase 3 trial that compared Atezolizumab in combination with carboplatin plus nab-paclitaxel ...
... is a class of prescription drugs in India appearing as an appendix to the Drugs and Cosmetics Rules, 1945 introduced in 1945. These are drugs which cannot be purchased over the counter without the prescription of a qualified doctor.The manufacture and sale of all drugs are covered under the Drugs and Cosmetics Act and Rules. It is revised at times based on the advice of the Drugs Technical Advisory Board, part of the Central Drugs Standard Control Organization[1] in the Ministry of Health and Family Welfare. The most recent schedule H (2006) lists 536 drugs from abacavir to zuclopenthixol.[2] However, enforcement of Schedule H laws in India is lax, compared to the more restrictive Schedule X, for which a mandatory documentation trail must be maintained.[3] ...
Carboplatin and busulfan dosing rely upon results from blood tests to calculate the optimal dose for each person. Simple blood ... Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and carboplatin. On the other hand, therapies ... Aziridines include thiotepa, mytomycin and diaziquone (AZQ). Cisplatin and derivatives include cisplatin, carboplatin and ...
The major elements are cisplatin, carboplatin, and oxaliplatin. It has been reported with full recovery among early-stage ...
Cisplatin ("Platinol") was given instead of carboplatin ("Paraplatin"). He resides in Rome, New York with his second wife, ...
Metal-Ammine Complexes Carboplatin, a widely used anticancer drug. Pentamminerhodium chloride, the dichloride salt one a ...
"AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer". "Trial shows benefit of 'BRCA-targeting' drug ... "Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel". ...
A combination of carboplatin and paclitaxel is often used. Advances techniques such as FISH and tissue of origin testing may ...
Either cisplatin or carboplatin is used as the platinum backbone. Development of targeted therapies has been less rapid for ...
Other platinum-containing anticancer drugs include cisplatin, carboplatin, and oxaliplatin. Triplatin belongs to the anticancer ...
Typical chemotherapy agents are a combination of paclitaxel and carboplatin. Cetuximab is also used in the treatment of throat ...
2009). "Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma". Archives of Ophthalmology. 127 (8 ... 2009). "Does a Nanomolecule of Carboplatin Injected Periocularly Help in Attaining Higher Intravitreal Concentrations?". ... carboplatin) has been developed, which has shown promising results in the treatment of retinoblastoma in animal models without ...
... has been compared with other platinum compounds used for advanced cancers, such as cisplatin and carboplatin. ... In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand trans-1,2-diaminocyclohexane in place of ... Oxaliplatin has less ototoxicity and nephrotoxicity than cisplatin and carboplatin. The compound features a square planar ...
Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC First Patient in CytoDyn's Triple-Negative ... "Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC". Retrieved 14 Aug 2020. " ... for use in combination with carboplatin for the treatment of patients with CCR5-positive mTNBC. In July 2019, CytoDyn announced ...
Rebimastat was used in a Paclitaxel/Carboplatin treatment in phase III. The results of the trial was a higher incidence of ...
Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for ... Carboplatin - a platinum-based antineoplastic drug, also an alkylating antineoplastic agent; Etoposide - a topoisomerase ...
"Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC". Retrieved 2019-02-19. " ...
Lokich J, Anderson N (January 1998). "Carboplatin versus cisplatin in solid tumors: an analysis of the literature". Ann. Oncol ... Go RS, Adjei AA (January 1999). "Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin". J ... pylori cisplatin and carboplatin - platinum containing anticancer agents gold salts such as auranofin - anti-inflammatory for ...
... and its myelosuppressive potency is similar to that of carboplatin. Dicycloplatin consists of carboplatin and cyclobutane-1,1- ... The second one is N-H...O which links between the ammonia group of carboplatin and oxygen of CBDC. It forms the two-dimensional ... Similar to carboplatin, dicycloplatin inhibits the proliferation of cancer cells by inducing cell apoptosis. When treated with ... Firstly, the bond between ammonia group of carboplatin and oxygen of CBDC breaks, thus inducing the formation of one- ...
The 5-year survival rate of patients with carboplatin was 82%, those without 68%. The European SIOP PNET 5 study is currently ... Depending on the randomization, half of the patients additionally received carboplatin daily during the radiation. ... July 2012). "Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a ... carboplatin, vincristine, or cyclophosphamide. In younger patients (less than 3-4 years of age), chemotherapy can delay, or in ...
December 2006). "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer". The New England Journal of ... de Castria TB, da Silva EM, Gois AF, Riera R (August 2013). "Cisplatin versus carboplatin in combination with third-generation ... Carboplatin is a chemotherapy agent that has a similar effect on a person's survival when compared to cisplatin, and has a ... This is based on an Eastern Cooperative Oncology Group study that found that adding bevacizumab to carboplatin and paclitaxel ...
Carboplatin Administer carboplatin (irritant):. *via IV infusion over 30 to 60 minutes ... High risk with carboplatin. Hypersensitivity risk increases with number of cycles of carboplatin. ... in the carboplatin arm. 42% cisplatin patients completed 3 cycles of adjuvant chemotherapy compared to 70% in the carboplatin ... cARBOplatin. 5 AUC (IV infusion) in 500 mL glucose 5% over 30 to 60 minutes (if estimated GFR is greater than 125 mL/min (i.e. ...
After 24 hours, close to 70% of carboplatin is excreted in the urine unchanged. This means that the dose of carboplatin must be ... Unlike cisplatin, carboplatin may be susceptible to alternative mechanisms. Some results show that cisplatin and carboplatin ... For this reason, "CBDCA" is sometimes used in the medical literature as an abbreviation referring to carboplatin. Carboplatin ... The diminished reactivity limits protein-carboplatin complexes, which are excreted. The lower excretion rate of carboplatin ...
Carboplatin Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Carboplatin may cause severe allergic reactions. If you experience an allergic reaction to carboplatin injection, it may begin ... Before receiving carboplatin injection,. *tell your doctor and pharmacist if you are allergic to carboplatin, cisplatin ( ... If you become pregnant while receiving carboplatin, call your doctor. Carboplatin may harm the fetus. ...
A list of US medications equivalent to Carboplatin Aurobindo is available on the website. ... Carboplatin Aurobindo is a medicine available in a number of countries worldwide. ... Ingredient matches for Carboplatin Aurobindo. Carboplatin. Carboplatin is reported as an ingredient of Carboplatin Aurobindo in ... Carboplatin Aurobindo. Carboplatin Aurobindo may be available in the countries listed below. ...
Find information about Carboplatin including usage and side effects. Browse our Drug Dictionary for generic drug names and ... Carboplatin is FDA approved to treat people who have certain kinds of cancer, including some blood cancers. Carboplatin may ... Some side effects of carboplatin (especially blood problems or numbness or tingling in fingers or toes) may be more likely to ... Patients Disease Information Treatment Types of Treatment Chemotherapy and Other Drug Therapies Drug Listings Carboplatin ...
today announced the launch of Carboplatin Injection, an antineoplastic agent, in four preservative-free vial presentations. ... Carboplatin is the first in a long list of products that we look forward to supplying from this facility," ... Carboplatin Injection is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior ... Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with ...
Carboplatin is a chemotherapy drug used for many cancers. Find out about how you have it, possible side effects and other ... Carboplatin is a chemotherapy treatment for many different types of cancer.. How carboplatin works. Carboplatin interferes with ... How you have carboplatin. You have this drug into your bloodstream. You have the treatment through a drip into your arm or hand ... You might have carboplatin every 3 to 4 weeks. Each 3 or 4 week period is a cycle of treatment. You might have between 4 to 6 ...
Carboplatin and etoposide chemotherapy is used to treat small cell cancers, including small cell lung cancer, small cell ... What is carboplatin and etoposide?. Carboplatin and etoposide chemotherapy is used to treat small cell cancers, including: * ... How carboplatin and etoposide are given. You will be given carboplatin and etoposide in the chemotherapy day unit or during a ... Your course of carboplatin and etoposide. You usually have a course of several cycles of treatment over a few months. ...
Carboplatin and etoposide chemotherapy is used to treat small cell cancers, including small cell lung cancer and small cell ... How carboplatin and etoposide are given. You will be given carboplatin and etoposide in the chemotherapy day unit or during a ... What is carboplatin and etoposide?. Carboplatin and etoposide chemotherapy is used to treat small cell cancers, including small ... Carboplatin and etoposide can cause side effects. Some of the side effects can be serious, so it is important to read the ...
Carboplatin is used together with other cancer medications to treat ovarian cancer. Carboplatin may also be used for purposes ... Carboplatin is a cancer medication that interferes with the growth of cancer cells and slows their growth and spread in the ... if you have received carboplatin in the past.. Do not use carboplatin if you are pregnant. It could harm the unborn baby. Use ... How is carboplatin given?. Carboplatin is injected into a vein through an IV. You will receive this injection in a clinic or ...
A Moderate Drug Interaction exists between carboplatin and ipilimumab. View detailed information regarding this drug ... Using CARBOplatin together with ipilimumab may increase the risk of nerve damage, which is a potential side effect of both ...
Information about this carboplatin-intravenous-route. Pregnancy Category. Explanation. All Trimesters. D. Studies in pregnant ... Infection-Carboplatin decreases your bodys ability to fight infection * Kidney disease-Effects may be increased because of ... Some side effects of carboplatin (especially blood problems or numbness or tingling in fingers or toes) may be more likely to ... on this medicine have been done only in adult patients and there is no specific information comparing use of carboplatin in ...
Diane: My husband has adenocarcinoma (NSCLC) with a large tumor in the right lung and many many metatastic nodules in both lungs, hence surgery and radiation is not an option. Furthermore, he had pleural effusions which were drained once by thoracentesis and supposedly permanently by a talc poudrage procedure. As I mentioned he is taking the taxol/carbo and tolerating it fairly well, but I suspect its not working (NSCLC in general does not respond to chemo as well as the more aggressive SCLC). Obviously, you have a different situation. Good luck. Keep me posted. Bess ------------------------------------------------------------------------ This is an automatically-generated notice. If youd like to be removed from the mailing list, please visit the Medicine-On-Line Discussion Forum at ,,, or send an email message to: [email protected] with the subject line blank and the body of the message containing the line: unsubscribe mol-cancer your-email-address where ...
The combination of carboplatin plus paclitaxel was less toxic and trended toward better survival as compared with 5- ... Carboplatin plus paclitaxel should now be considered the standard of care for patients with advanced anal cancer, in place of ... Cite this: Combo Carboplatin/Paclitaxel New Standard of Care for Anal Cancer - Medscape - Jun 25, 2020. ... Also supported by the NCI/ECOG, this is the phase 3 EA2176 of carboplatin/paclitaxel ± nivolumab (plus maintenance) and it will ...
Here are the warnings and precautions for Carboplatin. ... The FDA requires all potential medication risks for CARBOPLATIN ...
Of the patients treated with carboplatin, nearly 90 percent survived one year and nearly 63 percent were still alive at the ... Study Indicates Carboplatin Can Deliver Superior Performance When Compared to Other Chemotherapy Drugs. ... Carboplatin Shows Substantial Promise in Peritoneal Mesothelioma Treatment, Baron and Budd Reports. ... Mitomycin is an antibiotic used to fight tumors, while carboplatin is a platinum-based drug. ...
I went through 10 chemos (every week , , for 10 weeks) of taxol and carboplatin along with 34 radiation treatments to , , the ...
Hypersensitivity to carboplatin has been reported in 2% of the patients. These allergic reactions have been similar in nature ... Paraplatin (carboplatin aqueous solution) Injection is a cancer medication used to treat ovarian cancer. Paraplatin is ... Carboplatin, as a single agent or in combination, is significantly less emetogenic than cisplatin; however, patients previously ... Our Paraplatin (carboplatin aqueous solution) Injection Side Effects Drug Center provides a comprehensive view of available ...
It is concluded that, of the eight, diammine (1,1-cyclobutane dicarboxylato)platinum(II) (carboplatin, CBDCA, J … ... Preclinical studies identifying carboplatin as a viable cisplatin alternative Cancer Treat Rev. 1985 Sep;12 Suppl A:21-33. doi ... It is concluded that, of the eight, diammine (1,1-cyclobutane dicarboxylato)platinum(II) (carboplatin, CBDCA, JM8) had the ...
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.. Mok TS1, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, ... The 12-month rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel. The study met ... Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former ... or carboplatin (at a dose calculated to produce an area under the curve of 5 or 6 mg per milliliter per minute) plus paclitaxel ...
Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer. * ... Whether concomitant carboplatin and etoposide administration alters oblimersen sodium steady state level ... Pharmacokinetic parameters of G3139 in combination with paclitaxel and carboplatin. *Disease response as having either ...
Carboplatin Suppliers Directory - Find variety Carboplatin Suppliers, Manufacturers, Companies from around the World at , ... Carboplatin Anti-cancer Supplier , Carboplatin Factory Supplier , Pharmaceutical Carboplatin Supplier , Alpha Arbutin Supplier ... High Purity Carboplatin Supplier , High Purity Cas 41575-94-4 Carboplatin , High Quality Desloratadine Supplier , Cas 100643-71 ... Paclitaxel Carboplatin Supplier , Cas 41575-94-4 Supplier , Carboplatin Price Supplier , Glutathione Skin Whitening Injection ...
Information about this carboplatin-intravenous-route. Pregnancy Category. Explanation. All Trimesters. D. Studies in pregnant ... Carboplatin belongs to the group of medicines known as alkylating agents. It is used to treat cancer of the ovaries. It may ... After treatment with carboplatin has ended, normal hair growth should return.. Other side effects not listed may also occur in ... Infection-Carboplatin decreases your bodys ability to fight infection * Kidney disease-Effects may be increased because of ...
Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former ... Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/ ... Results: The 12-month rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel. The ... Conclusions: Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among ...
This led to the publication of an action letter on guidelines for carboplatin dosing in October 2010. (1) In this action letter ... The MDRD formula has been re-expressed using the new IDMS creatinine values but cannot be used for carboplatin dosing as it has ... Carboplatin-based chemotherapy remains the mainstay of treatment for many patients with gynecologic malignancies. In routine ... This prompted the GOG to switch from the Jelliffe to Cockcroft-Gault formula for estimation of GFR in carboplatin dosing. The ...
Carboplatin [Hospira, Inc.]: description, uses, side effects and safety, label, interactions, warnings , BioPortfolio ... 95% C.I. (Carboplatin - Cisplatin). (0.78, 1.23). (0.78, 1.30). The pattern of toxicity exerted by the carboplatin containing ... CALVERT FORMULA FOR CARBOPLATIN DOSING. Note: With the Calvert formula, the total dose of Carboplatin Injection is calculated ... What is Carboplatin Injection? Carboplatin Injection is a medicine that is used to treat cancer of the ovaries. It acts by ...
... carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be ... The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) ... Primary Objectives: a. To evaluate objective response rate of patients with metastatic uveal melanoma to Genasense-Carboplatin- ...
Drug: Carboplatin Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert ... Carboplatin and Bevacizumab for Recurrent Ependymoma. The safety and scientific validity of this study is the responsibility of ... After cycle 6, carboplatin should be discontinued, but bevacizubab may be continued at the descretion of the treating physician ... After cycle 6, carboplatin should be discontinued, but bevacizumab may be continued at the discretion of the treating physician ...
Carboplatin Login required for. Carboplatin. Please note that due to the German Advertising in the Health Care System Act ( ...
Same on the time frame, I ha Carboplatin concurrent with daily rads. The seven weekly doses of Carboplatin, Id go in about 90 ... Supposedly Carboplatin has a lot fewer side effects than Cisplatin. Anyone have experience with Carboplatin? ... Carboplatin, Taxal and Erbitux. I have had Cisplatin, Taxotere & 5FU during my first round of Squamus.. I was diagnosed with ... The Carboplatin usually only took an hour or so. The day I had chemo, Id also go down and do the rads after. ...
  • You should not receive carboplatin if you have severe bleeding or bone marrow suppression. (
  • Before you receive carboplatin, tell your doctor about all other medications you use. (
  • If you miss an appointment to receive carboplatin, contact your doctor as soon as possible to reschedule your appointment. (
  • Patients receive carboplatin IV over 1 hour followed by UCN-01 IV over 3 hours on day 1. (
  • Pets who receive carboplatin rarely lose their hair and, if they do, they are not bothered by it as much as people are. (
  • ARM B: Patients receive carboplatin IV and paclitaxel IV on day 1. (
  • The patients were randomly assigned in a 1:1 ratio to receive carboplatin plus etoposide (n=81) or oral topotecan (n=81). (
  • Patients undergo craniotomy and then receive carboplatin intracerebrally via CED over 72 hours. (
  • Some side effects of carboplatin (especially blood problems or numbness or tingling in fingers or toes) may be more likely to occur in the elderly. (
  • What are the possible side effects of carboplatin? (
  • Below are listed the potential side effects of carboplatin. (
  • Any side effects of carboplatin use with maitake, ginger or ecgg? (
  • Carboplatin and etoposide chemotherapy is used to treat small cell cancers, including small cell lung cancer, small cell bladder cancer and some types of gynaecological cancer. (
  • You will be given carboplatin and etoposide in the chemotherapy day unit or during a short stay in hospital. (
  • Carboplatin and etoposide chemotherapy can be given in different ways. (
  • Carboplatin and etoposide is a chemotherapy combination treatment used to treat different cancers. (
  • Carboplatin and etoposide can cause side effects. (
  • This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery. (
  • It is not yet known whether temozolomide and capecitabine may work better than cisplatin or carboplatin and etoposide in treating patients with this type of neuroendocrine carcinoma, called non-small cell neuroendocrine carcinoma. (
  • I. To assess the progression free survival (PFS) of platinum (cisplatin or carboplatin) and etoposide versus the PFS of temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas. (
  • However, some studies have suggested that the doublet of carboplatin and etoposide could have better outcomes. (
  • This study aims to compare the efficacy of carboplatin-etoposide and topotecan as a second-line treatment in patients with sensitive relapsed small-cell lung cancer (srSCLC). (
  • During a median follow-up of 22.7 months, the median progression-free survival was 4.7 months in the carboplatin-etoposide group, which was significantly longer than the topotecan group (2.7 months). (
  • There were two treatment-related deaths in the topotecan group, compared with no treatment-related deaths in the carboplatin-etoposide group. (
  • The research concluded that carboplatin-etoposide combination therapy was associated with better outcomes and safety profile than topotecan in patients with srSCLC. (
  • Aims: Carboplatin plus etoposide has modest efficacy in docetaxel-pretreated castration-resistant prostate cancer patients. (
  • We hypothesized that carboplatin-etoposide could still exert some therapeutic activity after docetaxel, cabazitaxel and either abiraterone or enzalutamide. (
  • Conclusion: Our preliminary findings support the hypothesis that carboplatin plus etoposide may yield some clinical benefit in a population of patients who failed all currently approved therapeutic options for prostate cancer. (
  • We report a case of a 21-year-old African-American man diagnosed with relapsed non-seminomatous germ cell tumor who received high-dose chemotherapy with carboplatin and etoposide following TIGER trial arm B off-protocol. (
  • Delayed rhabdomyolysis after high-dose chemotherapy with paclitaxel, ifosfamide, carboplatin, and etoposide regimen has not been previously reported and needs to be considered for preventive strategy and prompt diagnosis and treatment to avoid renal complications. (
  • The TIGER trial used the paclitaxel, ifosfamide, carboplatin, and etoposide (TI-CE) regimen for the HDCT arm: paclitaxel and ifosfamide (TI) as initial salvage chemotherapy along with autologous stem cell collection with granulocyte-colony stimulating factor (GCSF) support followed by carboplatin and etoposide (CE) [ 3 ]. (
  • Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. (
  • Bristol-Myers Squibb gained Food and Drug Administration (FDA) approval for carboplatin, under the brand name Paraplatin, in March 1989. (
  • Paraplatin ( carboplatin aqueous solution) Injection is a cancer medication used to treat ovarian cancer . (
  • Our Paraplatin (carboplatin aqueous solution) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. (
  • What is carboplatin (Paraplatin)? (
  • What is the most important information I should know about carboplatin (Paraplatin)? (
  • What should I discuss with my healthcare provider before receiving carboplatin (Paraplatin)? (
  • How is carboplatin given (Paraplatin)? (
  • What should I avoid while using carboplatin (Paraplatin)? (
  • NEW ORLEANS-First-line treatment with carboplatin (Paraplatin) and paclitaxel (Taxol) given every 4 weeks is well tolerated in patients with extensive small-cell lung cancer (SCLC), according to a multicenter phase II trial conducted in Italy and reported at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO). (
  • Unpleasant side effects from paraplatin (carboplatin) and taxol? (
  • Question about the side effects from paraplatin (carboplatin) and Taxol together? (
  • Paraplatin ( carboplatin ) http://www.Nlm.Nih.Gov/medlineplus/druginfo/meds/a695017.Html paclitaxel ( taxol ) http://www.Nlm.Nih.Gov/medlineplus/druginfo/meds/a607070.Html. (
  • What bad side effects might come with paraplatin (carboplatin) therapy? (
  • Carboplatin entered the U.S. market as Paraplatin ® in 1989 for initial treatment of advanced ovarian cancer in established combination with other approved chemotherapeutic agents. (
  • Carboplatin injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer. (
  • Carboplatin injection comes as a solution (liquid) to be injected over at least 15 minutes intravenously (into a vein) by a doctor or nurse in a medical facility. (
  • tell your doctor and pharmacist if you are allergic to carboplatin, cisplatin (Platinol), any other medications, or any of the ingredients in carboplatin injection. (
  • SCHAUMBURG, Ill., Nov. 4, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Carboplatin Injection, an antineoplastic agent, in four preservative-free vial presentations. (
  • According to IMS, for the 12 months ending September 2013, the US market for Carboplatin Injection approximated $30 million. (
  • Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. (
  • Carboplatin Injection is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. (
  • Call your doctor if you miss an appointment for your carboplatin injection. (
  • Anaphylactic-like reactions to Carboplatin Injection have been reported and may occur within minutes of Carboplatin Injection administration. (
  • Carboplatin Injection is supplied as a sterile, pyrogen-free, aqueous solution available in 50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL or 600 mg/60 mL multi-dose vials containing 10 mg/mL of carboplatin for administration by intravenous infusion. (
  • Each mL contains 10 mg carboplatin and Water for Injection, USP. (
  • The primary determinant of Carboplatin Injection clearance is glomerular filtration rate (GFR) and this parameter of renal function is often decreased in elderly patients. (
  • Dosing formulas incorporating estimates of GFR (see DOSAGE AND ADMINISTRATION ) to provide predictable Carboplatin Injection plasma AUCs should be used in elderly patients to minimize the risk of toxicity. (
  • Carboplatin is given as an intravenous (into the vein) injection. (
  • Carboplatin injection is contraindicated in patients with a history of severe allergic reactions to cisplatin or other platinum-containing compounds. (
  • Acetyl-l-carnitine 30 mg/mL in 5% dextrose for injection (D5W) was combined with carboplatin 4 mg/mL, paclitaxel 2 mg/mL, and docetaxel 0.74 mg/mL in glass vials. (
  • Carboplatin is a cancer medication used in chemotherapy combinations to treat ovarian cancer. (
  • Carboplatin is used together with other cancer medications to treat ovarian cancer. (
  • Data are based on the experience of 393 patients with ovarian cancer (regardless of baseline status) who received initial combination therapy with carboplatin and cyclophosphamide in two randomized controlled studies conducted by SWOG and NCIC (see Clinical Studies ). (
  • Data are based on the experience of 553 patients with previously treated ovarian carcinoma (regardless of baseline status) who received single-agent carboplatin. (
  • In two prospectively randomized, controlled studies conducted by the National Cancer Institute of Canada, Clinical Trials Group (NCIC), and the Southwest Oncology Group (SWOG), 789 chemotherapy naive patients with advanced ovarian cancer were treated with carboplatin or cisplatin, both in combination with cyclophosphamide every 28 days for six courses before surgical reevaluation. (
  • Carboplatin is indicated in the treatment of: advanced stage ovarian cancer of epithelial origin. (
  • Carboplatin, which is being used to treat ovarian and lung cancers, is getting known for its success rates in treating breast tumors. (
  • Carboplatin is a second-generation platinum analogue that has activity in refractory ovarian cancer similar to that of cisplatin (1). (
  • For this reason, we have begun to study the use of high-dose carboplatin therapy (800 mg/m 2 body surface area · cycle) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with refractory ovarian cancer. (
  • Carboplatin-Paclitaxel is the current standard in the first-line treatment of advanced ovarian cancer. (
  • Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. (
  • REDWOOD CITY, Calif., Feb. 20, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the initiation of patient treatment for its third multi-center Phase 1b clinical trial of OMP-54F28 (Fzd8-Fc) with carboplatin and paclitaxel in patients with platinum-sensitive ovarian cancer. (
  • The Phase 1b clinical trial of OMP-54F28 in combination with carboplatin and paclitaxel is a dose-escalation study in patients with recurrent platinum-sensitive ovarian cancer. (
  • Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults. (
  • Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. (
  • There is no significant quality of life advantage of cisplatin plus topotecan compared with paclitaxel plus carboplatin in the treatment of women with newly diagnosed ovarian cancer , according to a new study published online ahead of print in the journal Supportive Care in Cancer. (
  • A recent phase 3 study in women with newly diagnosed stage 2B or greater ovarian cancer found that cisplatin plus topotecan followed by carboplatin plus paclitaxel had a significantly lower response rate vs paclitaxel plus carboplatin. (
  • The findings of this analysis combined with the efficacy results of the phase 3 trial suggest that carboplatin plus paclitaxel should continue to be the standard of care for patients with newly diagnosed ovarian cancer. (
  • A recent phase III trial compared the efficacy of cisplatin-topotecan (a topoisomerase I inhibitor) followed by carboplatin-paclitaxel (Arm 1) versus paclitaxel-carboplatin (Arm 2) in women with newly diagnosed stage IIB or greater ovarian cancer . (
  • Array-based comparative genomic hybridization (CGH) was used to identify genetic alterations in 32 early-stage epithelial ovarian carcinomas homogeneously treated with single-agent carboplatin. (
  • The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. (
  • To evaluate objective response rate of patients with metastatic uveal melanoma to Genasense-Carboplatin-Paclitaxel (GCP) combination Secondary objectives: a. (
  • A significant unmet need in lung cancer has existed for decades, and we are now seeing that KEYTRUDA combined with pemetrexed and carboplatin shows a continued benefit for patients with metastatic nonsquamous non-small cell lung cancer in the first-line treatment of this disease," said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. (
  • Cohort G1 of the multicenter, open-label, phase 1/2 multi-cohort KEYNOTE-021 study evaluated the efficacy and safety of KEYTRUDA in combination with pemetrexed and carboplatin (KEYTRUDA + pem/carbo combination group) compared with pemetrexed and carboplatin (pem/carbo group) in 123 patients with metastatic, nonsquamous, EGFR- and ALK-negative NSCLC in the first-line treatment setting. (
  • I. To compare progression-free survival between patients with incurable unresectable locally advanced, or recurrent, or metastatic thymic carcinoma randomized to carboplatin-paclitaxel with or without ramucirumab. (
  • nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations. (
  • The FDA recently approved Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) for the initial treatment of people with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations. (
  • The results presented in this study showed no benefit to the overall population with the addition of bexarotene to standard chemotherapy with carboplatin and paclitaxel in the first-line setting with advanced and metastatic NSCLC. (
  • The purpose of this study is to offer pre-approval drug access of iniparib combined with gemcitabine and carboplatin, in order to provide potential clinical benefit to patients who have ER-, PR-, and HER2-negative metastatic breast cancer. (
  • Calvert formula: D o s e ( m g ) = A U C ⋅ ( G F R + 25 ) {\displaystyle Dose(mg)=AUC\cdot (GFR+25)} The typical area under the curve (AUC) for carboplatin ranges from 3-7 (mg/ml)*min. (
  • The patients received paclitaxel (200 mg/m 2 ) followed by carboplatin (dose equivalent to area under the curve of six) every 3 weeks for a maximum of six cycles. (
  • Patients with stage IIIB/IV NSCLC received (1:1) nab-paclitaxel 100 mg/m 2 on days 1, 8, and 15 or paclitaxel 200 mg/m 2 on day 1, both with carboplatin area under the curve 6 mg×min/mL on day 1 every 3 weeks. (
  • Appropriate patients will be enrolled in a 3+3 alternating dose escalating fashion, to a maximum dose of niraparib of 300mg daily and a maximum dose of carboplatin area under the curve (AUC) of 4. (
  • The main component of dose-dense chemotherapy is weekly paclitaxel (80 mg/m 2 ), but it would be interesting to know what is the difference between combination of triweekly cisplatin (20 mg/m 2 ) or triweekly carboplatin (carboplatin area under the curve 5-7 mg/mL per min [AUC 5-7]) in the dose-dense paclitaxel regimen. (
  • To obviate the need for melphalan dose restriction during tandem therapy, we report on the use of single agent carboplatin to the fellow eye. (
  • In terms of its structure, carboplatin differs from cisplatin in that it has a bidentate dicarboxylate (the ligand is CycloButane DiCarboxylic Acid, CBDCA) in place of the two chloride ligands, which are the leaving groups in cisplatin. (
  • For this reason, "CBDCA" is sometimes used in the medical literature as an abbreviation referring to carboplatin. (
  • It is concluded that, of the eight, diammine (1,1-cyclobutane dicarboxylato)platinum(II) (carboplatin, CBDCA, JM8) had the features most desirable to merit its clinical evaluation. (
  • Therefore, in this study, we investigated the real-world efficacy and safety of carboplatin (CBDCA) plus nab-paclitaxel (nab-PTX) as a first-line regimen for NSCLC patients with ILD. (
  • The goal of this clinical research study is to learn if the combination of bevacizumab and carboplatin can help to control recurrent pendymoma. (
  • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. (
  • Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434). (
  • The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (
  • 6] This level of activity in recurrent disease led to a randomized phase III trial in the frontline setting, GOG 218, which tested the inclusion of bevacizumab both with IV paclitaxel/carboplatin and as a maintenance strategy. (
  • 8] GOG 252 incorporates bevacizumab into IV/IP therapy, while also trying to address the toxicity issue by comparing a modified GOG 172 regimen to an IP carboplatin regimen. (
  • Data was presented from this randomized phase II trial of 454 patients in a 4-arm trial with paclitaxel alone or combined with either bevacizumab (Avastin) or carboplatin, or all three treatments combined. (
  • The data did not confirm benefit of carboplatin or bevacizumab to patient outcomes, but nor did the presenter insist that the data refuted efficacy. (
  • Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. (
  • Bevacizumab has recently been demonstrated to prolong overall survival when added to carboplatin and paclitaxel for chemotherapy-naïve patients with nonsquamous nonsmall-cell lung cancer (NSCLC). (
  • We designed this single treatment arm, phase 2 trial to determine whether the combination of carboplatin, docetaxel, and bevacizumab is tolerable and prolongs progression-free survival of chemotherapy-naïve patients with advanced, nonsquamous NSCLC. (
  • Forty patients were treated with up to 6 cycles of carboplatin (AUC 6), docetaxel (75 mg/m(2)), and bevacizumab (15 mg/kg) on Day 1 every 21 days. (
  • Carboplatin, docetaxel, and bevacizumab were feasible and effective for front-line treatment of advanced, nonsquamous NSCLC. (
  • Carboplatin is in a class of medications known as platinum-containing compounds. (
  • A multicentre, phase II study of carboplatin and paclitaxel (CbP) in chemotherapy-naïve patients with advanced thymic carcinoma has shown that the treatment has promising efficacy compared with standard anthracycline-based chemotherapy. (
  • Phase II study of carboplatin in untreated inoperable non-small cell lung cancer. (
  • Between January 2010 and December 2016, 40 women with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC EOC, FTC, or PPSC were enrolled, including 18 treated with paclitaxel-cisplatin and the remaining 22 treated with paclitaxel-carboplatin. (
  • Because the effectiveness of adding aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic chemotherapy is unknown as well, researchers sought to compare the efficacy and safety of triple vs double antiemetic therapy in patients with advanced NSCLC receiving carboplatin-based chemotherapy. (
  • Concentration-time data of ultrafilterable platinum of 178 patients (280 courses, 3,119 samples) with different types of cancer receiving carboplatin-based chemotherapy in conventional and high doses were available. (
  • He received one cycle of combined chemotherapy with paclitaxel and carboplatin. (
  • The two regimens had different toxicity profiles, with more neutropenia and anemia observed in the carboplatin plus paclitaxel group, but more nausea, vomiting, mucositis, and diarrhea with cisplatin plus FU. (
  • Carboplatin appears to have a spectrum of clinical toxicity different from that of cisplatin: at therapeutically equivalent doses, the dose-limiting toxicity for carboplatin is myelosuppression, with comparatively little renal or neurologic toxicity (1-3). (
  • I. Determine the maximum tolerated dose, dose limiting toxicity and other toxicities of UCN-01 when combined with carboplatin. (
  • At this stage, the data is provocative but it remains an individual decision if carboplatin is appropriate for all triple negative breast cancers, given the high toxicity and inconclusive data. (
  • I. To evaluate the frequency and severity of toxicity of carboplatin-paclitaxel with or without ramucirumab in this patient population. (
  • I. Establish the maximum tolerated dose and define the toxicity profile of carboplatin delivered intracerebrally via convection enhanced delivery (CED) for patients with high grade glial neoplasms. (
  • In high-dose chemotherapy regimens with stem cell support, toxicities, such as nephrotoxicity, ototoxicity, central nervous system toxicity, and peripheral nervous system toxicity, have been associated with a higher carboplatin exposure ( 3 , 6 - 11 ). (
  • BACKGROUND: To investigate a novel schedule of gemcitabine (G), paclitaxel (P), and carboplatin (C), based on preclinical studies demonstrating greater activity and decreased toxicity of administering P prior to C. MATERIAL/METHODS: The effect of the P and C drug sequence on tumor cell viability was assessed with a tetrazolium assay on T24 bladder and DU145 prostate cancer cells. (
  • Each mL of sterile aqueous solution contains carboplatin 10 mg. (
  • Researchers found that nausea and vomiting improve more with paclitaxel plus carboplatin during and after treatment. (
  • A total of 49 patients with advanced NSCLC receiving gemcitabine plus carboplatin chemotherapy were studied. (
  • The InterAAct trial has established carboplatin-paclitaxel as a new standard of care in this population in the frontline setting," commented Sarbajit Mukherjee, MD, assistant professor of oncology at Roswell Park Comprehensive Cancer, Buffalo, New York, who was approached for an independent comment. (
  • The scientists will be testing this finding on 150 BRCA breast cancer patients, 75 with each mutation, who will be administered carboplatin or docetaxel, to check out which one is more effective. (
  • Carboplatin 4 mg/mL, paclitaxel 1.2 mg/mL, and docetaxel 0.74 mg/mL are physically and chemically compatible with acetyl-l-carnitine 30 mg/mL in D5W during a simulated 4-hour Y-site administration. (
  • Wagstaff AJ, Ward A, Benfield P, et al: Carboplatin, a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. (
  • Forward-looking statements, including the Company's expectations related to the U.K. Phase I/II REOLYSIN paclitaxel and carboplatin trial and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. (
  • Carboplatin exposure, expressed as area under the plasma concentration versus time curve (AUC), has been related both to severity of thrombocytopenia and leukopenia as well as to therapeutic outcome (reviewed in refs. (
  • IMpower130 is a Phase III, multicentre, open-label, randomised study evaluating the efficacy and safety of Tecentriq in combination with carboplatin and nab -paclitaxel versus chemotherapy (carboplatin and nab-paclitaxel) alone for chemotherapy-naïve patients with stage IV non-squamous NSCLC. (
  • IMpower131 is a Phase III, open-label, multicentre, randomised study evaluating the efficacy and safety of Tecentriq in combination with carboplatin and nab -paclitaxel or Tecentriq in combination with carboplatin and paclitaxel versus chemotherapy (carboplatin and nab -paclitaxel) alone in people with stage IV squamous-cell NSCLC who have not been previously treated with chemotherapy. (
  • Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in a. (
  • Mitomycin is an antibiotic used to fight tumors, while carboplatin is a platinum-based drug. (
  • In the narrative section that follows, the incidences of adverse events are based on data from 1,893 patients with various types of tumors who received carboplatin as single-agent therapy. (
  • British scientists have conducted a research on mice which has revealed that cancer cells with BRCA2 mutations are twenty times more receptive to carboplatin, and that BRCA1 tumors are between five and twenty times more receptive. (
  • Phase I trial to study the effectiveness of combining UCN-01 with carboplatin in treating patients who have advanced solid tumors. (
  • The primary endpoint will be identifying the recommended phase 2 dose (RP2D) and schedule of niraparib plus carboplatin, as well as establishing the anti-tumor efficacy of niraparib plus carboplatin as determined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. (
  • This phase I clinical trial studies the side effects and best dose of carboplatin administered by convection enhanced delivery into the tumor in patients with high grade brain tumors (gliomas). (
  • Cohorts of 3-6 patients receive escalating doses of carboplatin and UCN-01 until the maximum tolerated dose (MTD) is determined. (
  • PURPOSE: To determine the cell-killing activity of varying doses of carboplatin, graded hyperthermia, and the combination of carboplatin and hyperthermia in the treatment of a transgenic murine retinoblastoma cell line. (
  • Relative to cisplatin, the greatest benefit of carboplatin is its reduced side effects, particularly the elimination of nephrotoxic effects. (
  • Before you begin treatment with carboplatin, you and your doctor should talk about the good this medicine will do as well as the risks of using it. (
  • Carboplatin/paclitaxel 2018-06-02 00:00:00 Reactions 1704, p87 - 2 Jun 2018 Worsening of pleural effusion and increasing respiratory distress: case report A 44-year-old man developed worsening of pleural effusion and increasing respiratory distress during treatment with carboplatin and paclitaxel [dosages and routes not stated]. (
  • Combining UCN-01 with carboplatin may kill more tumor cells. (
  • We hypothesize that in this HR deficient patient population, the addition of niraparib to carboplatin will lead to significant anti-tumor responses with acceptable toxicities. (
  • Advanced NSCLC patients with low RRM1 mRNA expression both in peripheral blood and in tumor tissue could benefit from gemcitabine/carboplatin chemotherapy. (
  • ERCC1 mRNA expression in tumor tissue may be a predictive and prognostic indicator in advanced NSCLC patients receiving gemcitabine/carboplatin chemotherapy. (
  • Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (
  • The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of demonstrating non-inferiority. (
  • nab-Paclitaxel/carboplatin was efficacious and tolerable in patients ≥70 years with squamous NSCLC. (
  • KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated results from KEYNOTE-021, Cohort G1, which studied KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, in combination with pemetrexed and carboplatin (pem/carbo) in the first-line treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. (
  • The clinical pharmacology of carboplatin, co-administered with paclitaxel, was investigated in a dose-finding and sequence-finding study in 56 previously untreated patients with non-small cell lung cancer (NSCLC). (
  • Adding aprepitant to palonosetron and dexamethasone provided no improvement in carboplatin-induced emesis in patients with advanced non-small cell lung cancer (NSCLC) , a new study published online ahead of print in the journal Lung Cancer has shown. (
  • Based upon these results, the authors performed a randomized study in elderly patients with advanced NSCLC comparing monotherapy with gemcitabine or vinorelbine to combination therapy with carboplatin and paclitaxel. (
  • The investigators concluded that carboplatin plus paclitaxel is very well tolerated, but was not sufficiently active in this study to warrant a phase III comparison with standard chemotherapy regimens for extensive SCLC. (
  • Assessment of gemcitabine/carboplatin combination in patients with advanced-stage hepatocellular carcinoma (HCC) in a phase II trial for safety and efficacy. (
  • In two separate, single center phase II studies, a different combination of the three active agents (Carboplatin, Paclitaxel and Topotecan) has been tested. (
  • Here, we report the outcomes of a retrospective analysis of a subset of patients ≥70 years with squamous histology from the Phase III trial that evaluated nab-paclitaxel/carboplatin vs paclitaxel/carboplatin. (
  • Primary objectives of the trial are to evaluate safety of this combination regimen and determine a recommended Phase 2 dose for OMP-54F28 in combination with carboplatin and paclitaxel. (
  • Based on the favorable safety profile observed in our Phase 1a clinical study, we look forward to exploring the tolerability and efficacy of OMP-54F28 with carboplatin and paclitaxel. (
  • This phase II trial studies how well enzalutamide, carboplatin, and paclitaxel work in treating patients with endometrioid endometrial cancer that is stage III-IV or has come back (recurrent). (
  • The study is a prospective, single arm, non-randomized, open label phase II trial, designed to study the safety and efficacy of a medical device, the NovoTTF-100L concomitant with Pemetrexed and cisplatin or carboplatin in Malignant Pleural Mesothelioma patients. (
  • This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. (
  • This phase II trial studies how well nivolumab, nab-paclitaxel, and carboplatin induction chemotherapy followed by response-based locoregional therapy works in treating patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma that has spread from where it started to nearby tissue or lymph nodes. (
  • During the treatment-induction phase, people in Arm A received Tecentriq and carboplatin on day 1 of each 21-day cycle, and nab -paclitaxel on days 1, 8 and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit, whichever occurred first. (
  • During the treatment-induction phase, people in Arm A received four or six cycles of Tecentriq plus carboplatin and paclitaxel, given on day one of each 21-day cycle. (
  • During the treatment-induction phase, people in Arm B received four or six cycles of Tecentriq, carboplatin and nab -paclitaxel. (
  • A Randomized Phase III Trial Comparing Bexarotene/Carboplatin/Paclitaxel vs. Carboplatin/Paclitaxel in Chemotherapy-Naive Patients with Advanced or. (
  • ONCY ) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for patients with advanced cancers. (
  • This is an outstanding response rate in this difficult-to-treat patient population, and formed the basis of the Phase III pivotal program now being developed for REOLYSIN in combination with carboplatin/paclitaxel for head and neck cancer patients," said Dr. Brad Thompson, President and CEO of Oncolytics. (
  • An independent, confirmatory Phase II trial using the same combination of REOLYSIN and carboplatin/paclitaxel for patients with head and neck cancers is currently underway in the U.S. (
  • Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. (
  • CARBOPLATIN (KAR boe pla tin) is a chemotherapy drug. (
  • Carboplatin is the only platinum-based chemotherapy medicine approved by the U.S. Food and Drug Administration (FDA) to treat breast cancer. (
  • Carboplatin is only found in individuals that have used or taken this drug. (
  • Bristol-Myers Squibb also licensed carboplatin, a second generation platinum drug with fewer side effects, in 1979. (
  • Carboplatin may cause severe allergic reactions. (
  • You should not receive this medication if you are allergic to carboplatin or similar medications such as oxaliplatin (Eloxatin) or cisplatin (Platinol). (
  • Should your pet have an allergic reaction to carboplatin, it would develop upon administration, and your veterinarian and the hospital staff are trained to treat patients for allergic reaction. (
  • The platinum drugs cisplatin, carboplatin, and oxaliplatin are highly utilized in the clinic and as a consequence are extensively studied in the laboratory setting. (
  • The patients received first-line therapy with carboplatin (AUC 6) plus paclitaxel (175 mg/m² over 3 hours) on day 1, every 4 weeks, for a median of six cycles. (
  • Case 1: A 71-year-old woman, who was diagnosed with stage IIa non-small cell lung cancer in 2013, had received induction chemotherapy with 4 cycles of pemetrexed, carboplatin and pembrolizumab. (
  • Patients in the KEYTRUDA + pem/carbo combination group received KEYTRUDA (200 mg), pemetrexed (500 mg/m 2 ) and carboplatin (AUC 5 mg/mL/min) every three weeks for four cycles followed by KEYTRUDA every three weeks. (
  • In routine practice, the carboplatin dose is calculated using an estimated creatinine clearance that is derived from formulas that incorporate the patient's serum creatinine. (
  • Therefore, in patients with relatively low serum creatinine the IDMS method generated abnormally low values, leading to an overestimation of creatinine clearance and consequently higher calculated carboplatin doses. (
  • Historically, the Gynecologic Oncology Group (GOG) used a different formula, the Jelliffe equation, to estimate creatinine clearance for carboplatin dosing. (
  • In patients with creatinine clearances below 60 mL/min, the total body and renal clearances of carboplatin decrease as the creatinine clearance decreases. (
  • Carboplatin is FDA approved to treat people who have certain kinds of cancer, including some blood cancers. (
  • Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies. (
  • The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group. (
  • Number of patients with a neutropenia event, identified from the lab data as a worsening in absolute neutrophil count from baseline to a CTC grade 3 or above which Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel). (
  • Incidences of grade 3/4 neutropenia (50% vs 63%), leukopenia (29% vs 37%), fatigue (3% vs 13%), and peripheral neuropathy (3% vs 13%) were lower, but those of thrombocytopenia (21% vs 10%) and anemia (21% vs 7%) were higher with nab-paclitaxel/carboplatin vs paclitaxel/carboplatin. (
  • In terms of adverse events (AEs), patients in paclitaxel-carboplatin group had more AEs, with a higher risk of neutropenia and grade 3/4 neutropenia, and the need for a longer period to complete the front-line chemotherapy, and the latter was associated with worse outcome for patients. (
  • My friend gets carboplatin and Taxol (paclitaxel) combined and longterm - are there side effects to this? (
  • Seems Taxol (paclitaxel) + carboplatin (+erbitux) weekly instead of 3 weekly has min side efex. (
  • The trial is designed to assess the efficacy and safety of niraparib plus carboplatin in patients with evidence of HRD. (
  • After 39 rounds of radiation, starting full strength Abraxane/Carboplatin on 3/3. (
  • The nadir of this myelosuppression usually occurs 21-28 days after the first treatment, after which the blood cell and platelet levels in the blood begin to stabilize, often coming close to its pre-carboplatin levels. (
  • The use of carboplatin is mainly limited by myelosuppression. (
  • The Calvert formula is a widely applied algorithm for the a priori dosing of carboplatin based on patients glomerular filtration rate (GFR) as accurately measured using the 51 Cr-EDTA clearance. (
  • The MDRD formula has been re-expressed using the new IDMS creatinine values but cannot be used for carboplatin dosing as it has not been validated for this purpose. (
  • Carboplatin, therefore, exhibits linear pharmacokinetics over the dosing range studied (300 mg/m to 500 mg/m). (
  • Therefore, various dosing equations have been proposed to calculate a priori an appropriate dose for a target exposure of carboplatin in a patient with a known GFR ( 12 , 16 ). (
  • Combined treatment studies used these carboplatin dosages with each of the graded hyperthermia exposure temperatures at each exposure time. (
  • In these studies, Carboplatin and Paclitaxel were given at standard doses and schedules, followed sequentially by Topotecan which was well tolerated at a dose of 1.25 mg/m2/day given for five days and repeated every 21 days. (
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. (
  • The 12-month rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel. (
  • Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. (
  • The company stated that it does not intend to launch paclitaxel as albumin‑bound nanoparticles with carboplatin for untreated non‑small‑cell lung cancer when potentially curative surgery or radiation therapy or both are unsuitable, in the UK. (
  • Carboplatin plus paclitaxel should now be considered the standard of care for patients with advanced anal cancer , in place of the standard combination of 5-fluorouracil (5-FU) and cisplatin , say experts discussing results from InterAAct, the first international prospective randomized trial in advanced anal cancer. (
  • Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer [published online ahead of print November 7, 2015]. (
  • Carboplatin has also been used for adjuvant therapy of stage 1 seminomatous testicular cancer. (
  • This has led to carboplatin based adjuvant therapy being generally preferred over adjuvant radiotherapy in clinical practice. (
  • With an additional five months of follow-up, we are seeing continued benefits in overall response rate and progression-free survival with KEYTRUDA plus pemetrexed/carboplatin," said Dr. Vassiliki Papadimitrakopoulou, section chief thoracic medical oncology, UT MD Anderson Cancer Center. (
  • Eligible patients will be enrolled, baseline tests will be performed and the patients will be treated continuously with the device concomitant with weekly pemetrexed and cisplatin or carboplatin until disease progression. (